

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted articles (R), abstracts (A), book reviews (B), and Supplement (S).

Acid, fatty,

- Capillary gas chromatographic analysis of mycolic acid cleavage products, cellular fatty acids, and alcohols of *M. xenopi*. Luquin, M., *et al.* (A) 917

Acid-fast bacilli,

- Significance of culture granules of leprosy derived acid-fast chemoautotrophic nocardioform bacteria. Chakrabarty, A. N., *et al.* (A) 582

Acquired immunodeficiency syndrome (AIDS),

- AIDS and leprosy. Turk, J. L. and Rees, R. J. W. (A) 890
 Antimicrobial synergism against *M. avium* complex strains isolated from patients with acquired immune deficiency syndrome. Yajko, D. M., *et al.* (A) 596
 Association of leprosy and infection with the human immunodeficiency virus; two observations. Janssen, F., *et al.* (A) 571
 Challenging the stigma: from leprosy to AIDS. Law, A. S. (A) 352
 Diagnosis of *Mycobacterium* bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. Eng, R. H. K., *et al.* (A) 728
 Hypothesis: Does vaccination with bacille Calmette-Guérin protect against AIDS? Kal-lenius, G., *et al.* (A) 729
 Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Lamoureux, G., *et al.* (A) 592
 Prevalence et evolution de l'infection au virus humain d'immunodeficiency (VIM) chez les lepreux en Haiti. Pean, C., *et al.* (A) 306

Adenosine triphosphate (ATP),

- Effects of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., *et al.* (O) 615
 Measurement of ATP content of *M. leprae*—its application to the determination of viability and drug sensitivity screening. Katoch, V. M., *et al.* (A) 321
 Studies on adenylate kinase (ATP: AMP phosphotransferase) of *M. marinum* (ATCC 927). Batra, P. P., *et al.* (A) 912

Africa,

- African Regional Workshop on Youth Mobilization for Leprosy Work. (N) 558
 Enquetes d'évaluation par sondage de la prevalence de l'endemie lepreuse en Afrique Centrale. Josse, R., *et al.* (A) 323
 Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Lamoureux, G., *et al.* (A) 592
 The anatomical distribution of single leprosy lesions in an African population, and its implications for the pathogenesis of leprosy. Ponnighaus, J. M., *et al.* (A) 307

American Leprosy Missions (ALM),

- Brazil rehabilitation expert elected to President's chair at American Leprosy Missions. (N) 560

Amikacin,

- Amikacin, ciprofloxacin, and imipenem treatment for disseminated *M. avium* complex infection of beige mice. Inderlied, C. B., *et al.* (A) 591

Antibody(ies),

- A 28-kDa protein from *M. leprae* is a target of the human antibody response in lepro-matous leprosy. Cherayil, B. J. and Young, R. A. (A) 575
 An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., *et al.* (A) 304
 Antineural antibodies in leprosy sera: further characterization of the antigens. Benjamins, J. A., *et al.* (A) 711

[Assay of antibody level in sera of leprosy patients with <i>M. smegmatis</i> ELISA.] Wu, Q., <i>et al.</i> (A)	718
Association of tuberculosis and <i>M. tuberculosis</i> -specific antibody levels with HLA. Bothamley, G. H., <i>et al.</i> (A)	727
Characterization of an antibody-binding epitope from the 18-kDa protein on <i>M. leprae</i> . Doherty, T. M., <i>et al.</i> (A)	719
[Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., <i>et al.</i> (A)	918
Demonstration of antidapsone antibody in leprosy patients. Agrewala, J. N., <i>et al.</i> (C)	687
Detection of phenolic glycolipid I of <i>M. leprae</i> and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., <i>et al.</i> (A)	897
[Determination of antibodies to mycobacterial antigens in tuberculosis by the method of erythroimmunoabsorption with a rosette marker.] Plaksin, D. Y., <i>et al.</i> (A)	140
Development of Epstein-Barr virus transformed human B-cell lines secreting anti- <i>M. leprae</i> antibodies. Moudgil, K. D., <i>et al.</i> (A)	579
Effect of multidrug therapy on the levels of antibodies to <i>M. leprae</i> glycolipid-I in the leprosy spectrum. Vaishnavi, C., <i>et al.</i> (A)	580
Effect of suppressor cells on antibody producing cells in mice infected with <i>M. leprae</i> . Vaishnavi, C., <i>et al.</i> (A)	718
Evaluation of chemotherapy in leprosy by monitoring <i>M. leprae</i> specific antibody titers in patients. Sinha, S., <i>et al.</i> (A)	305
Failure to detect antibodies to HIV-1 in sera from patients with mycobacterial infections. Malkovsky, M., <i>et al.</i> (C)	866
Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., <i>et al.</i> (A)	899
Frequency and polyreactivity of human antibodies to phen GL-1 from leprosy patients defined by anti-idiotypes. Zumla, A., <i>et al.</i> (A)	304
Lymphoproliferation and <i>in vitro</i> antibody synthesis in leprosy patients. Yandava, C. N., <i>et al.</i> (O)	633
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., <i>et al.</i> (A)	325
Ontogenesis of antibodies in rhesus monkeys infected with <i>M. leprae</i> . Mukherjee, R., <i>et al.</i> (A)	309
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., <i>et al.</i> (A)	897
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., <i>et al.</i> (O)	735
Quantitative antibody ELISA for leprosy. Hasan, R., <i>et al.</i> (O)	766
Selective coating of <i>M. leprae</i> surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in <i>M. leprae</i> -infected macrophages. Rastogi, N. and Frehel, C. (A)	326
Serum antibodies of normals and leprosy patients show equal binding to peripheral nerve. Ghaswala, P. S., <i>et al.</i> (C)	690
Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Gelber, R. H., <i>et al.</i> (O)	744
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Cree, I. A., <i>et al.</i> (A)	576
Specific anti- <i>M. leprae</i> PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., <i>et al.</i> (O)	794
Use of nonconventional antigen, <i>M. habana</i> , in detecting <i>M. leprae</i> antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., <i>et al.</i> (A)	580
Antibodies, monoclonal,	
A monoclonal antibody based competition radioimmunoassay for monitoring anti- <i>M. leprae</i> antibodies in leprosy patients and contacts. Sinha, S., <i>et al.</i> (A)	573
Human gut wall reactivity to monoclonal antibodies against <i>M. avium</i> glycolipid in relation to Crohn's disease (preliminary results). Blaauwgeers, J. L. G., <i>et al.</i> (A)	912
Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., <i>et al.</i> (A)	582

- Identification of *M. leprae* antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., *et al.* (O) 652
- Monoclonal antibodies to 33 kD protein of *M. tuberculosis* with varying epitope specificities. Rambukkana, A., *et al.* (A) 903
- Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., *et al.* (A) 303
- Polyspecificity of human monoclonal antibodies reactive with *M. leprae*, mitochondria, ssDNA cytoskeletal proteins, and the acetylcholine receptor. Duggan, D. B., *et al.* .. (A) 576
- Serology of mycobacteria: characterization of antigens recognized by monoclonal antibodies. Young, D. B. and Mehlert, A. (A) 719
- Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* (A) 901
- Use of monoclonal antibodies in the identification of mycobacterial antigens. Kolk, A. H. J., *et al.* (A) 322
- Antigen(s),**
- A competition ELISA for the detection of mycobacterial antigen in tuberculosis exudates. Ramkisson, A., *et al.* (A) 730
- A passive hemagglutination test for leprosy using a synthetic disaccharide antigen. Petchclai, B., *et al.* (A) 305
- A peptidoglycan protein complex purified from *M. leprae* cell walls contains most or all immunodominant *M. leprae* T-cell antigens. Mutis, T., *et al.* (O) 788
- A protein antigen of *M. leprae* is related to a family of small heat shock proteins. Nerland, A. H., *et al.* (A) 585
- A study of incidence of Australia antigen and derangements in liver function tests in leprosy. Nayak, K. C., *et al.* (A) 710
- An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., *et al.* (A) 304
- Antigenic profile of ICRC bacilli with special reference to isolation of immunogenic subunit. Chirmule, N. B., *et al.* (A) 137
- Antineural antibodies in leprosy sera: further characterization of the antigens. Benjamins, J. A., *et al.* (A) 711
- Arabinogalactan; a complementary antigen to phenolic glycolipid in leprosy diagnosis. Roy, A., *et al.* (A) 580
- Bacterial antigen processing in macrophages infected with the obligate intracellular bacterium, *M. avium*. de Chastellier, C. and Lang, T. (A) 914
- Chemical synthesis of an artificial antigen containing the trisaccharide hapten of *M. leprae*. Marino-Albernas, J., *et al.* (A) 714
- [Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., *et al.* (A) 918
- Comparative studies of antigenic glycolipids of mycobacteria related to the leprosy bacillus. Minnikin, D. E., *et al.* (A) 908
- Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* (A) 914
- Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* (A) 899
- Detection of a specific *M. leprae* antigen in the urine of leprosy patients. Mahon, A. C., *et al.* (A) 326
- Detection of leprosy antigenuria through DOT-ELISA. Singh, N. B. and Choudhary, A. (A) 573
- Detection of phenolic glycolipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* (A) 897
- Differential recognition of *Leishmania aethiopsica* antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Akuffo, H. O., *et al.* (A) 727
- Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., *et al.* (A) 590
- Evaluation of a phenoglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* (A) 917

Evaluation of an enzyme immunoassay based on sonicate supernatant antigens of <i>Mycobacterium w</i> for immunodiagnosis of leprosy. Moudgil, K. D., <i>et al.</i> (A)	138
Evaluation of <i>M. leprae</i> antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., <i>et al.</i> (A)	899
Evaluation of natural phenolic glycolipid (GPL) and artificial antigen in the serodiagnosis of leprosy. Wu, Q.-Z., <i>et al.</i> (A)	305
Genomic and amino acid sequence of the <i>M. leprae</i> 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., <i>et al.</i> (A)	318
Homology of the 70-kilodalton antigens from <i>M. leprae</i> and <i>M. bovis</i> with the <i>M. tuberculosis</i> 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., <i>et al.</i> (A)	583
Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., <i>et al.</i> (A)	582
Identification of <i>M. leprae</i> antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., <i>et al.</i> (O)	652
Identification of mycobacterial antigens for "ELISA" serology in the diagnosis of leprosy and tuberculosis. Das, P. K., <i>et al.</i> (A)	898
Identification of mycobacterial antigens recognized by T lymphocytes. Lamb, J. R., <i>et al.</i> (A)	714
IIC8 hybridoma B cells can present recombinant 65-kDa mycobacterial antigen to T cells. Mshana, R. N., <i>et al.</i> (A)	319
Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., <i>et al.</i> (A)	905
Inyecciones de <i>M. vaccae</i> muertas inducen respuestas intradermicas frente antigenos solubles del <i>M. leprae</i> en 50% de pacientes lepromatosos. Torres, P., <i>et al.</i> (A)	320
Leprosy and hepatitis B surface antigen. Vaishnavi, C., <i>et al.</i> (A)	896
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., <i>et al.</i> (A)	325
Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., <i>et al.</i> (A)	303
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., <i>et al.</i> (A)	897
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., <i>et al.</i> (O)	735
Preliminary evaluation of a <i>M. tuberculosis</i> phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., <i>et al.</i> (A)	151
Recognition of a category of responders to group ii, slow-grower associated, antigens amongst Kuwaiti senior school children, using a statistical model. McManus, I. C., <i>et al.</i> (A)	592
Recognition of <i>M. leprae</i> Antigens. Ottenhoff, T. and de Vries, R. R. P. (A)	139
Recognition of mycobacterial antigens by sera from patients with leprosy. Vega-Lopez, F., <i>et al.</i> (A)	581
Relapse in LL patients after antileprosy ICRC vaccine: its significance to antigenic variability of <i>M. leprae</i> . Bapat, C. V. (A)	349
Selection of recombinant DNA clones expressing the 12K and 36K <i>M. leprae</i> antigens in <i>E. coli</i> K12. Hartskeerl, R. A., <i>et al.</i> (A)	328
Selective coating of <i>M. leprae</i> surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in <i>M. leprae</i> -infected macrophages. Rastogi, N. and Frehel, C. (A)	326
Serologic responses to <i>M. leprae</i> -specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., <i>et al.</i> (A)	309
Serological responses of patients with lepromatous and tuberculoid leprosy to 30-, 31-, and 32-kilodalton antigens of <i>M. tuberculosis</i> . Rumschlag, H. S., <i>et al.</i> (A)	140
Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Burgess, P. J., <i>et al.</i> (A)	144

- Serology of mycobacteria: characterization of antigens recognized by monoclonal antibodies. Young, D. B. and Mehlert, A. (A) 719
- Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Gelber, R. H., *et al.* (O) 744
- Skin lesion in strain 13 guinea pig induced by a human non-myelin antigen in dorsal roots. Crawford, C. L., *et al.* (A) 308
- Specific lysis by CD8+ T cells of Schwann cells expressing *M. leprae* antigens. Steinhoff, U. and Kaufmann, S. H. E. (A) 141
- Specificity and antigenicity of mycoside G and other glycolipids from *M. marinum*. Cruaud, P., *et al.* (A) 913
- Specificity of proliferative response of human CD8 clones to mycobacterial antigens. Rees, A., *et al.* (A) 904
- Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., *et al.* (A) 582
- T cell epitopes on the 36K and 65K *M. leprae* antigens defined by human T cell clones. van Schooten, W. C. A., *et al.* (A) 141
- T cell reactivity of leprosy patients and their household contacts to mycobacterial sonicates and affinity purified antigens. Adams, E., *et al.* (A) 318
- T cell responses to fractionated *M. leprae* antigens in leprosy. The lepromatous non-responder defect can be overcome *in vitro* by stimulation with high molecular weight *M. leprae* components. Ottenhoff, T., *et al.* (A) 326
- T-cell responses to the *M. leprae* 18 kD antigen. Harris, D. P., *et al.* (A) 319
- The 65 kilodalton antigen of mycobacteria. Shinnick, T. (A) 329
- The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., *et al.* (A) 315
- The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* (A) 579
- The use of a "universal" yeast expression vector to produce an antigenic protein of *M. leprae*. Booth, R. J., *et al.* (A) 575
- Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* (A) 901
- Use of monoclonal antibodies in the identification of mycobacterial antigens. Kolk, A. H. J., *et al.* (A) 322
- Use of nonconventional antigen, *M. habana*, in detecting *M. leprae* antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., *et al.* (A) 580
- Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* (A) 717
- Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. (A) 334
- Use of soluble antigens in leprosy epidemiology. Gupte, M. D. and Anantharamun, D. S. (A) 577
- Armadillo(s),**
- Armadillos in leprosy research: current status. Storrs, E. E. and Burchfield, H. P. (A) 308
- Comparison of the distribution of indigenous human and armadillo leprosy in Louisiana, U.S.A. Truman, R. W. and Kumaresan, J. A. (A) 334
- Light- and electron-microscopic study of *M. leprae*-infected armadillo nerves. Liu, T.-C., *et al.* (O) 65
- Ocular leprosy in the armadillo and man—a histopathological study. Jacob, M. (A) 355
- Serodiagnosis of leprosy infection in 9 banded armadillos. Eggelte, T. A., *et al.* (A) 310
- Viability of *M. leprae* in soil and dead armadillo tissue and its significance. Harris, E. B., *et al.* (A) 323
- [Wild leprosy in *Dasybus novemcinctus*.] Martinez, A. R., *et al.* (A) 724
- Arthritis,**
- Clinical and laboratory studies of arthritis in leprosy. Atkin, S. L., *et al.* (A) 895
- Inefficacy of thalidomide on rat adjuvant-induced arthritis and lack of arthrogenicity of Hansen bacilli. Tsutsumi, S. and Gidoh, M. (A) 721

Assay(s) (see also ELISA),

A comparative evaluation of serological assays for lepromatous leprosy. Mwantha, J., <i>et al.</i> (A)	138
Appraisal of two <i>M. leprae</i> -specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Sinha, S., <i>et al.</i> (O)	24
[Assay of antibody level in sera of leprosy patients with <i>M. smegmatis</i> ELISA.] Wu, Q., <i>et al.</i> (A)	718
Comparison of <i>in vitro</i> Fc receptor assay with other methods including mouse foot pad method. Jagannathan, R., <i>et al.</i> (A)	321
Correlation of <i>in vitro</i> Fc receptor assay with <i>in vivo</i> mouse foot pad method. Jagannathan, R., <i>et al.</i> (A)	584
Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., <i>et al.</i> (A)	303
Serodiagnostic potentialities of enzyme-linked immunosorbent assay (ELISA) using mannophosphoinositides of <i>M. tuberculosis</i> H37Rv. Mehta, P. K. and Khuller, G. K. (A)	593
Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., <i>et al.</i> (A)	901

Autopsy,

Leydig cells observed in autopsy cases of the national leprosarium, Okukomyoen (Japan). Obara, A., <i>et al.</i> (A)	345
--	-----

Bacilli,

A concentration method for detection and quantitation of bacillaemia in leprosy and its comparison with other techniques. Nagesha, C. N., <i>et al.</i> (A)	584
Antigenic profile of ICRC bacilli with special reference to isolation of immunogenic subunit. Chirmule, N. B., <i>et al.</i> (A)	137
Charting of organic sites showing the presence of bacilli and specific infiltrate on a series of 126 necropsies from leprosy patients. Tentative of association with cause of death. Lombardi, C., <i>et al.</i> (A)	345
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., <i>et al.</i> (A)	136
[Tuberculoid leprosy with necrotizing neuritis and numerous bacilli in the fistulae.] de Menezes, J. A., <i>et al.</i> (A)	569

Bacilli, ICRC,

Antigenic profile of ICRC bacilli with special reference to isolation of immunogenic subunit. Chirmule, N. B., <i>et al.</i> (A)	137
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., <i>et al.</i> (A)	136

Bacteremia,

Diagnosis of <i>Mycobacterium</i> bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. Eng, R. H. K., <i>et al.</i> (A)	728
---	-----

Bacteriology,

Bacteriology of infected hands and feet in leprosy patients. Abdulkadir, S. (A)	708
---	-----

BCG (bacille Calmette-Guérin),

BCG infection induces responsiveness to dead <i>M. leprae</i> in hamsters; a Mitsuda-like reaction. Mariano, M. and Ferreira, C. S. A. (A)	902
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., <i>et al.</i> (A)	914
Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments. Katoch, K., <i>et al.</i> (A)	900
Implications of prior BCG vaccination programmes in the community on the protective efficacy of new antileprosy vaccines. Radhakrishna, S., <i>et al.</i> (A)	588
Sensitisation by mycobacteria and the effects of BCG on children attending schools in the slums of Bombay. Stanford, J. L., <i>et al.</i> (A)	595
The distribution and implications of BCG scars in northern Malawi. Fine, P. E. M., <i>et al.</i> (A)	728

Transformation of BCG with plasmid DNA. Lugosi, L., <i>et al.</i> (A)	907
Use of recombinant antigens expressed in <i>Escherichia coli</i> K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of <i>M. bovis</i> BCG. Thole, J. E. R., <i>et al.</i> (A)	717
Belgium,	
La lèpre importée en Belgique: diagnostic. Pattyn, S. R. (A)	572
Biopsy,	
Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., <i>et al.</i> (A)	899
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. McDougall, A. C. (C)	114
Drs. Jacob and Mathai reply. Jacob, M. and Mathai, R. (C)	114
Sural nerve biopsy findings in leprosy: a qualitative and quantitative light and electron microscopic study in 4 treated cases of lepromatous spectrum. Gibbels, E., <i>et al.</i> (A)	137
The role of nerve biopsies in the diagnosis and management of leprosy. Nilsen, R., <i>et al.</i> (A)	895
Blood,	
Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Simpson, L. O. (A)	595
Diagnosis of <i>Mycobacterium</i> bacteremia in patients with acquired immunodeficiency syndrome by direct examination of blood films. Eng, R. H. K., <i>et al.</i> (A)	728
[Pathologic changes and bacillation of blood vessels in LL and BL leprosy.] Liu, J., <i>et al.</i> (A)	578
Reduced numbers of Leu 8(+) cells in peripheral blood of lepromatous leprosy patients (LL). Sasiain, M. de C., <i>et al.</i> (A)	325
Bone,	
[Bone changes in leprosy; a study of distal lesions by means of soft X-rays.] Yebra Sotillo, I., <i>et al.</i> (A)	574
[Viking-age skeleton exhibiting pathologic changes in the dentition and maxillary and mandibular bones—scurvy or leprosy?] Lorentsen, M. and Solheim, T. (A)	564
Book reviews,	
<i>A Guide to Leprosy Control</i> (2nd ed.) by the World Health Organization. (B)	124
<i>Essays on Leprosy by Oxford Medical Students</i> by R. J. Ryan and A. C. McDougall. . . (B)	124
<i>Fulfillment Through Leprosy</i> by T. N. Jagadisan. (B)	122
<i>Handbook of Leprosy</i> (4th edition) by W. H. Jopling and A. C. McDougall. (B)	122
<i>How to Diagnose and Classify Leprosy: a Study Guide</i> by R. E. Pfaltzgraff. (B)	123
<i>Kalaupapa National Historical Park and the Legacy of Father Damien (a Pictorial History)</i> by Anwei V. Skinses Law and Richard A. Wisniewski. (B)	562
<i>La Maladie de Hansen en Haiti</i> by C. Pean. (B)	123
<i>Leprosy and Human Dignity</i> by Max Gruner. (B)	562
<i>Leprosy for Medical Practitioners and Paramedical Workers</i> by R. H. Thangaraj and S. J. Yawalkar. (B)	124
<i>Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday</i> by the World Health Organization. (B)	122
<i>Olivia: My Life of Exile in Kalaupapa</i> by Olivia Robello Breitha (B)	562
<i>Orientation in Leprosy for Doctors.</i> (N)	119
<i>Peripheral Denervation of the Foot</i> by Carl D. Enna. (B)	121
<i>Peripheral Denervation of the Hand</i> by Carl D. Enna. (B)	121
<i>Proceedings of the International Congress on Medical and Social Rehabilitation of the Disabled in the Third World Countries with Emphasis on the Rehabilitation of the Leprosy Patient.</i> (B)	563
<i>Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988.</i> (B)	124
<i>Sixth Report of the WHO Expert Committee on Leprosy.</i> (B)	125
<i>Studies on Leprosy; Supplement 3</i> by N. Veeraraghavan. Franzblau, S. G. and Hastings, R. C. (B)	705
<i>Tuberculosis and Leprosy</i> by Richard J. W. Rees. Cowley, S. A. (B)	888

Borderline leprosy,

- A florid case of borderline-lepromatous leprosy. Raman, J. and Fisher, D. (A) 896
- Comprehensive management of recent nerve damage in borderline leprosy on an out-patient basis. Udaya, K. K. and Suneetha, S. (A) 338
- Destruction of ala nasi and loss of columella in borderline tuberculoid leprosy—a case report. Siddappa, K., *et al.* (A) 711
- Effect of multidrug treatment (paucibacillary regimen) on the clinical and histological features of tuberculoid and borderline tuberculoid cases. Kumar, T. S., *et al.* (A) 346
- Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* (A) 346
- Multiple synovial swellings in BT leprosy; a case report. Chattopadhyay, S. P., *et al.* . . (A) 895
- Occurrence of reversal reactions in BT patients during WHO paucibacillary leprosy MDT (1982). Reddy, P. K. (A) 131
- [Pathologic changes and bacillation of blood vessels in LL and BL leprosy.] Liu, J., *et al.* (A) 578
- The high prevalence of testicular involvement in lepromatous (LL) as compared to borderline lepromatous (BL) leprosy patients. Gebhard, J. F. and Rea, T. H. (A) 344
- The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., *et al.* (A) 144
- Type 1 reaction in borderline leprosy—a Dhoolpet experience. Suneetha, S. and Udaya, K. K. (A) 315
- Un traitement logique des nevrites lepreuses tuberculoides et borderline aigues ou subaigues: la desensibilisation progressive a la lepromine. Saint-André, P., *et al.* (A) 339

Brazil,

- Brazil rehabilitation expert elected to President's chair at American Leprosy Missions. (N) 560
- [Epidemiological aspects of hanseniasis in Uberlandia, Minas Gerais (Brazil) (1973–1983).] Livorato, F., *et al.* (A) 146
- Evaluation of efficiency, efficacy and effectiveness of prevention and treatment of physical disabilities in leprosy control in Brazil. Goncalves, A., *et al.* (A) 342
- Gradual setting up of multidrug therapy (WHO-MDT) in Brazil. Oliveira, M. L. W., *et al.* (A) 333
- Induction of the late hypersensitivity reaction to DNCB in patients with different clinical forms of hanseniasis in Brazil. Azulay, R. D. (A) 310
- Leprosy control in the state of Amazonas, based on MDT (WHO/82). Talhari, S., *et al.* (A) 334
- Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday* by the World Health Organization. (B) 122
- Results after 5 years of multidrug therapy (MDT) according to WHO recommendations for leprosy patients in Curupaiti (Brazil). Andrade, V. L. G., *et al.* (A) 335
- The participation of Hansen's disease patient in all the activities of control in Brazil. Nogueira, W. and Pereira, G. F. M. (A) 348
- The trends of Hansen's disease in Brazil. Paula Motta, C. and Zuniga G., M. (A) 333

Burma,

- A 15 year survey of Burmese amputees. Pe, H. (A) 726

Caribbean,

- Genetic susceptibility to leprosy on a Caribbean island: linkage analysis with five markers. Abel, L., *et al.* (O) 465

Cell(s),

- An *in vitro* evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. Anderson, R., *et al.* (A) 727
- Effect of preincubation on the proliferative response to antigen by cells from leprosy patients and healthy controls. Mullins, R. J. and Basten, A. (O) 777
- In vitro* analysis of the cellular mechanisms involved in immunity to tuberculosis. Kaufmann, S. H. E. (A) 729

- Intralesional cellular and soluble immunoregulatory events in type 1 (“reversal”) reactions. Scollard, D. M., *et al.* (A) 312
- Intracellular parasitism of parenchymal cells by *M. leprae*. Job, C. K., *et al.* (O) 659
- Leydig cells observed in autopsy cases of the national leprosarium, Okukomyoen (Japan). Obara, A., *et al.* (A) 345
- M. leprae* induced suppressor cells in the polar clinical forms of leprosy. Sasiain, M. del C., *et al.* (A) 325
- [Morphological characteristics of cell cultures from human and animal lepromas and the effect of antileprosy drugs on them.] Vishnevetsky, F. E., *et al.* (A) 909
- Purification of *M. leprae* with special reference to the effects of purified *M. leprae* vaccines and host macrophage cell functions. Saito, H., *et al.* (A) 904
- Reduced numbers of Leu 8(+) cells in peripheral blood of lepromatous leprosy patients (LL). Sasiain, M. de C., *et al.* (A) 325
- Reduced suppressor cell response to *M. leprae* in lepromatous leprosy. Sasiain, M. del C., *et al.* (A) 715
- Studies in human leprosy lesions *in situ* using suction-induced blisters. 1. Cellular components of new, uncomplicated lesions. Rangdaeng, S., *et al.* (O) 492
- The role of CD8+ cells in resistance and delayed hypersensitivity reactions in *M. lepraemurium* infection. Curtis, J., *et al.* (A) 308
- Cells, B,**
- Development of Epstein-Barr virus transformed human B-cell lines secreting anti-*M. leprae* antibodies. Moudgil, K. D., *et al.* (A) 579
- IIC8 hybridoma B cells can present recombinant 65-kDa mycobacterial antigen to T cells. Mshana, R. N., *et al.* (A) 319
- Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* (A) 717
- Cells, endothelial,**
- Endothelial cell bacillation in human leprosy—ultrastructural aspects. Mukherjee, A., *et al.* (A) 345
- Cells, natural killer (NK),**
- [Determination of ability of producing IL-2 and activity of NK in multibacillary leprosy.] Xiong, S., *et al.* (A) 719
- Cells, Schwann,**
- Effect of *M. leprae*-infected Schwann cells and their supernatant on lymphocyte neuroglia interaction. Mehta, R., *et al.* (A) 902
- Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of *M. leprae* by Schwann cells *in vitro*. Chaudhury, A., *et al.* (A) 893
- Evidence for phagosome-lysosome fusion in *M. leprae*-infected murine Schwann cells. Steinhoff, U., *et al.* (A) 717
- In vitro* analysis of the role of Schwann cells in leprosy. Steinhoff, U., *et al.* (A) 339
- In vitro* interaction of *M. leprae*-infected Schwann cells and splenic cells. Mehra, R., *et al.* (A) 579
- Specific lysis by CD8+ T cells of Schwann cells expressing *M. leprae* antigens. Steinhoff, U. and Kaufmann, S. H. E. (A) 141
- T lymphocytes, mononuclear phagocytes, Schwann cells and *M. leprae*. Kaufmann, S. H. E., *et al.* (A) 900
- Cells, T,**
- A *M. leprae*-specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Anderson, D. C., *et al.* (A) 136
- A peptidoglycan protein complex purified from *M. leprae* cell walls contains most or all immunodominant *M. leprae* T-cell antigens. Mutis, T., *et al.* (O) 788
- Activation of $\gamma\delta$ T cells in the primary immune response to *M. tuberculosis*. Janis, E. M., *et al.* (A) 900
- Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* (A) 914

Evidence that <i>M. leprae</i> specific helper T cells exist in lepromatous leprosy patients. Gill, H. K., <i>et al.</i> (A)	319
Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., <i>et al.</i> (A)	899
HLA-DR, -DQ DNA genotyping and T-cell receptor RFLPs in leprosy. Jazwinska, E. C. and Serjeantson, S. W. (A)	145
HLA-DR-restricted antigen-induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed <i>M. leprae</i> . Mustafa, A. S. and Qvigstad, E. (O)	1
Identification of subpopulations of CD4+ and CD8+ T cells in leprosy granulomas. Rea, T. H. and Modlin, R. L. (A)	327
IICB hybridoma B cells can present recombinant 65-kDa mycobacterial antigen to T cells. Mshana, R. N., <i>et al.</i> (A)	319
Killing of human monocytes by specific cytotoxic T cells and nonspecific, MHC unrestricted killer cells after activation by mycobacterial antigens. Kaleab, B., <i>et al.</i> (A)	311
Limiting dilution of murine T cell response to mycobacterial antigens. Launois, P., <i>et al.</i> (A)	901
Mechanisms of <i>M. leprae</i> -specific T-cell deficiency in lepromatous leprosy. Bach, M.-A. and Launois, P. (A)	574
Molecular pattern of the T-cell repertoire in leprosy patients and their relatives. Mendez-Samperio, P., <i>et al.</i> (A)	319
Molecular study of the T cell repertoire in family contacts and patients with leprosy. Mendez-Samperio, P., <i>et al.</i> (A)	902
Mycobacteria-reactive Lyt-2+ T cell lines. De Libero, G., <i>et al.</i> (A)	898
Observations on T-cell subpopulations in type II reactions. Kalyanasundaram, K., <i>et al.</i> (A)	714
Regulation of T cell responsiveness against mycobacterial antigens by HLA class 2 immune response genes. de Vries, R. R. P. (A)	713
Screening for T cell reactivity of recombinant <i>M. leprae</i> peptides. Jayaraman, T., <i>et al.</i> (A)	319
Specific lysis by CD8+ T cells of Schwann cells expressing <i>M. leprae</i> antigens. Steinhoff, U. and Kaufmann, S. H. E. (A)	141
T cell epitopes on the 36K and 65K <i>M. leprae</i> antigens defined by human T cell clones. van Schooten, W. C. A., <i>et al.</i> (A)	141
T cell reactivity of leprosy patients and their household contacts to mycobacterial sonicates and affinity purified antigens. Adams, E., <i>et al.</i> (A)	318
T cell responses to fractionated <i>M. leprae</i> antigens in leprosy. The lepromatous non-responder defect can be overcome <i>in vitro</i> by stimulation with high molecular weight <i>M. leprae</i> components. Ottenhoff, T., <i>et al.</i> (A)	326
T-cell responses to the <i>M. leprae</i> 18 kD antigen. Harris, D. P., <i>et al.</i> (A)	319
The classical and alternate pathways of T cell activation are impaired in leprosy. Muthukkaruppan, V., <i>et al.</i> (A)	579
Use of recombinant antigens expressed in <i>Escherichia coli</i> K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of <i>M. bovis</i> BCG. Thole, J. E. R., <i>et al.</i> (A)	717
Cell-mediated immunity (CMI),	
Clinical trial with clofazimine for treating erythema dyschromicum perstans; evaluation of cell-mediated immunity. Piquero-Martin, J., <i>et al.</i> (A)	919
Evaluation of cell-mediated immunity on leprosy patients in Taiwan: a preliminary report. Liu, M.-F., <i>et al.</i> (A)	901
The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., <i>et al.</i> (A)	315
The reconstruction of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., <i>et al.</i> (A)	714
Chemotherapy (see also Therapy),	
Appraisal of two <i>M. leprae</i> -specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Sinha, S., <i>et al.</i> (O)	24
Detection of phenolic glycolipid I of <i>M. leprae</i> for monitoring the chemotherapy of leprosy. Cho, S.-N., <i>et al.</i> (A)	303

Effect of chemotherapy on viability of <i>M. leprae</i> as determined by ATP content, morphological index and FDA-EB fluorescence staining. Katoch, V. M., <i>et al.</i> (O)	615
[Ethionamide in combined chemotherapy.] Carvalho Costa, I. M., <i>et al.</i> (A)	565
Evaluation of chemotherapy in leprosy by monitoring <i>M. leprae</i> specific antibody titers in patients. Sinha, S., <i>et al.</i> (A)	305
Evaluation of <i>M. leprae</i> antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., <i>et al.</i> (A)	899
Evaluation of two multidrug regimens in hospitalized multibacillary cases. Chattopadhyay, S. P., <i>et al.</i> (A)	892
Field trial of short course combined chemotherapy in paucibacillary leprosy. Day, R. S. and Teterissa, M. R. (C)	340
Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council (A)	591
Histopathologic observations on the persistence of <i>M. leprae</i> in the skin of multibacillary leprosy patients under chemotherapy. Wabitsch, K. R. and Meyers, W. M. (A)	581
Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., <i>et al.</i> (A)	339
Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., <i>et al.</i> (A)	346
PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., <i>et al.</i> (O)	735
Possible use of B-lactam antibiotics in the treatment of Hansen's disease. Prabhakaran, K., <i>et al.</i> (A)	317
<i>Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988.</i> (B)	124
Progress in chemotherapy research under THELEP programme. Ji, B.-H., <i>et al.</i> (A)	336
Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Mukhopadhyay, A., <i>et al.</i> (A)	918
The design and development of novel broad spectrum antimycobacterial compounds from thioureas. Devasthale, S. V., <i>et al.</i> (A)	316
[Tridrug regimen in multibacillary leprosy for two years.] Chen, J., <i>et al.</i> (A)	707

Children,

A pilot study of three potential vaccines for leprosy in Bombay school children. Stanford, J. L., <i>et al.</i> (A)	350
A report on six cases of histoid variety of lepromatous leprosy in children. Mohan, L., <i>et al.</i> (A)	710
Analyses of leprosy incidence in 2261 children of leprosy patients. Chu, Z.-Z., <i>et al.</i> (A)	332
Identification of "high risk group" of leprosy in children using serological and lepromin test: a preliminary report. Naik, S. S., <i>et al.</i> (A)	910
Indeterminate leprosy in a population survey and in the subsequent follow-up of children. Bechelli, L. M. (A)	305
[Investigation of occurrence of the disease in 2261 children of parents with leprosy.] Chu, Z., <i>et al.</i> (A)	723
Leprosy in infants—report on two cases. Girdhar, A., <i>et al.</i> (O)	472
Leprosy in young urban children. Sehgal, V. N. and Sehgal, S. (A)	147
Recognition of a category of responders to group ii, slow-grower associated, antigens amongst Kuwaiti senior school children, using a statistical model. McManus, I. C., <i>et al.</i> (A)	592
Sensitisation by mycobacteria and the effects of BCG on children attending schools in the slums of Bombay. Stanford, J. L., <i>et al.</i> (A)	575
Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Ly, H. M., <i>et al.</i> (A)	724
3299 cases of children leprosy in Fujian. Shao, K.-W., <i>et al.</i> (A)	306
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., <i>et al.</i> (O)	45
Vaccination and skin test studies on the children of leprosy patients. Stanford, J. L., <i>et al.</i> (O)	38

China, People's Republic of,

- [Endemicity and control of leprosy in Hebei Province.] Tan, D., *et al.* (A) 724
- [Endemicity of leprosy and its control in Zhejiang Province.] Chen, D. (A) 144
- [Endemicity of leprosy in Shaanxi Province.] Qian, A., *et al.* (A) 587
- Investigation of 1692 cases of leprosy ophthalmia in Guangdong Province. Lu, B.-X.,
et al. (A) 355
- Short-term multidrug therapy in multibacillary leprosy; review of 80 cases in two prov-
inces of China. Li, H.-Y., *et al.* (A) 336
- Studies on social medicine of leprosy in China. Ye, G.-Y., *et al.* (A) 353
- The possibility of leprosy eradication in Shandong Province by year 2000. Fan, Y.-L.
and Zhao, T. (A) 333

Cholesterol,

- Estimation of high density lipoprotein cholesterol in the diagnosis of lepromatous lep-
rosy. Kumar, N., *et al.* (A) 571

Chromatography,

- Certain aspects of dapsone metabolism in leprosy patients as studied by high perfor-
mance liquid chromatography (HPLC) and qualitative screening tests. Irudaya Raj,
P. P., *et al.* (A) 129
- Preliminary results on the detection of mycolic acids from *M. leprae* by gel permeation
chromatography and proton nuclear resonance spectroscopy. Gan, S. C., *et al.* (A) 583

Ciprofloxacin,

- Amikacin, ciprofloxacin, and imipenem treatment for disseminated *M. avium* complex
infection of beige mice. Inderlied, C. B., *et al.* (A) 591
- In vitro* activity of ciprofloxacin in combination with standard antituberculous drugs
against *M. tuberculosis*. Uttley, A. H. C. and Collins, C. H. (A) 151

Classification,

- Evolution of the classification of leprosy. Sehgal, V. N., *et al.* (A) 890
- The reactional tuberculoid—its position in the classification of leprosy. Opromolla, D.
V. A., *et al.* (A) 314

Clinics,

- Factors influencing clinic attendance for treatment of leprosy. Vadher, A. (A) 348

Clinical,

- A clinical, immunological and histological study in neuritic leprosy patients. Girdhar,
B. K., *et al.* (A) 338
- A double-blind controlled clinical trial to assess the role of antihistamines in the treat-
ment of multibacillary leprosy. Thomas, A., *et al.* (A) 568
- A quantitative study of the relationship between systemic immunity and local histo-
pathological changes in untreated leprosy. Beck, J. S., *et al.* (A) 346
- A study into bacteriological positivity and treatment of beggar leprosy patients. Rao, P.
S., *et al.* (A) 911
- Adreno-cortical function in leprosy. Garg, R., *et al.* (A) 569
- Case study of patients released from observation. Singh, S. L. and Bedenbender, H. ... (A) 307
- Chromoblastomycosis in a residual patch of leprosy. Pavithran, K. (A) 134
- Clinical and laboratory studies of arthritis in leprosy. Atkin, S. L., *et al.* (A) 895
- Clinical pharmacokinetics of clofazimine; a review. Holdiness, M. R. (A) 893
- Clinical trial with clofazimine for treating erythema dyschromicum perstans; evaluation
of cell-mediated immunity. Piquero-Martin, J., *et al.* (A) 919
- Controlled clinical trial for evaluation of antimicrobial drug activity against *M. leprae*.
Grosset, J. H. and Ji, B.-H. (E) 529
- Correlation of clinical and histopathologic features in untreated macular lesions of
leprosy—a study of 100 cases. Sheno, S. D. and Siddappa, K. (A) 135
- Current clinical status of uveitis in leprosy under various drug regimes. Samanta, S. K.,
et al. (A) 355
- Diagnostic value of cardinal signs/symptoms in paucibacillary leprosy. Sirumban, P.,
et al. (A) 125
- Disability survey of 1480 cases of leprosy. Zheng, T.-S., *et al.* (A) 315

- Effect of multidrug treatment (paucibacillary regimen) on the clinical and histological features of tuberculoid and borderline tuberculoid cases. Kumar, T. S., *et al.* (A) 346
- Immunoregulatory mechanism of endogenous glucocorticoid in leprosy. Sheriff, S., *et al.* (A) 312
- Interpretation of published papers on controlled clinical trials. Waters, M. F. R. (C) 556
- Involvement of palate and cheek in leprosy. Kumar, B., *et al.* (A) 134
- M. avium-intracellulare* infection associated with hairy-cell leukemia. Maurice, P. D. L., *et al.* (A) 149
- M. leprae* induced suppressor cells in the polar clinical forms of leprosy. Sasiain, M. del C., *et al.* (A) 325
- Male hormonal insufficiency in multibacillary Hansen's disease—prevalence and clinical manifestations. Frankel, R. I. (A) 313
- Morphometric study of stratum corneum in leprosy. Okhandiar, R. P., *et al.* (A) 710
- [Ocular leprosy—clinical statistics.] Watanabe, I., *et al.* (A) 573
- Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., *et al.* (A) 317
- Serology during the clinical course of treated leprosy. Li, F., *et al.* (A) 303
- Status of multibacillary patients "lost to follow up." Muliylil, J. and Thangavel, N. (A) 903
- The management of reaction in leprosy. Pfaltzgraff, R. E. (E) 103
- [Thermography as a method for diagnosing leprosy.] Yebra Sotillo, I., *et al.* (A) 574
- Thyroid hormones in leprosy patients. Babybin, E. S. (A) 895
- Tuberculoid granuloma in a clinically normal looking skin. Haldar, S. R., *et al.* (A) 133
- Tuberculoid leprosy on hairy scalp: a case report. Ghorpade, A., *et al.* (A) 133
- Turn-over of stratum corneum in leprosy. Okhandiar, R. P., *et al.* (A) 139
- Clofazimine,**
- Clinical pharmacokinetics of clofazimine; a review. Holdiness, M. R. (A) 893
- Clinical trial with clofazimine for treating erythema dyschromicum perstans; evaluation of cell-mediated immunity. Piquero-Martin, J., *et al.* (A) 919
- Clofazimine and dapsone compliance in leprosy. Ellard, G. A., *et al.* (A) 128
- Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for *M. avium* complex. Lindholm-Levy, P. J. and Heifets, L. B. (A) 149
- Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. (A) 132
- [Effects of clofazimine on the patients with ENL dependent upon corticosteroids.] Yu, X., *et al.* (A) 568
- Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* (A) 899
- Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* (A) 733
- The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., *et al.* (A) 315
- The effect of treatment with rifampicine, clofazimine and dapsone in multibacillary leprosy in the field for three years. Li, W.-Z., *et al.* (A) 341
- Truitement de la lèpre rurale par une dose unique de rifampicine complétée par l'association sulfone clofazimine en autotraitement. Languillon, J. L. (A) 341
- Cloning,**
- A cloned DNA fragment for identification of *M. tuberculosis*. Patel, R. J., *et al.* (A) 730
- Characterization of *M. leprae* cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., *et al.* (A) 715
- HLA-DR-restricted antigen-induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed *M. leprae*. Mustafa, A. S. and Qvigstad, E. (O) 1
- Selection of recombinant DNA clones expressing the 12K and 36K *M. leprae* antigens in *E. coli* K12. Hartskeerl, R. A., *et al.* (A) 328
- Specificity of proliferative response of human CD8 clones to mycobacterial antigens. Rees, A., *et al.* (A) 904

T cell epitopes on the 36K and 65K <i>M. leprae</i> antigens defined by human T cell clones. van Schooten, W. C. A., <i>et al.</i> (A)	141
Complement,	
Comprehensive evaluation of complement components in the course of type I (lepra) and type II (ENL) reactions. Sehgal, V. N., <i>et al.</i> (A)	716
Differences in uptake of mycobacteria by human monocytes; a role for complement. Swartz, R. P., <i>et al.</i> (A)	595
Influence of <i>in vitro</i> administered immune complexes on serum levels of complement and circulating immune complexes in <i>M. leprae</i> infected mice. Vaishnavi, C., <i>et al.</i> (A)	586
Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., <i>et</i> <i>al.</i> (A)	131
The complement profile in leprosy. He, H.-M., <i>et al.</i> (A)	326
The effect of anti-reactional drugs on complement components in the type II, erythema nodosum leprosum, reaction. Sehgal, V. N., <i>et al.</i> (A)	135
Congresses,	
<i>Proceedings of the International Congress on Medical and Social Rehabilitation of the</i> <i>Disabled in the Third World Countries with Emphasis on the Rehabilitation of the</i> <i>Leprosy Patient.</i> (B)	563
XIII International Leprosy Congress transactions. (S)	229
Control of leprosy,	
Comparative epidemiological and operational assessment of a vertical and an integrated leprosy control program. Parkhe, S. M., <i>et al.</i> (A)	330
[Endemicity and control of leprosy in Hebai Province.] Tan, D., <i>et al.</i> (A)	724
[Endemicity of leprosy and its control in Zhejiang Province.] Chen, D. (A)	144
[Evaluation of effects of leprosy control using the life table.] Yang, Z. (A)	588
Experience in leprosy control in a developing country. Due, L. K., <i>et al.</i> (A)	332
Implications of genetics for the epidemiology and control of leprosy. Fine, P. E. M. . . (A)	586
Integrated leprosy control in the Gambia. Kinteh, S. B. and Bouchier, V. A. (A)	323
Managing leprosy patient care in partnership with local communities. Sorensen, B. H. (A)	331
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., <i>et al.</i> (A)	897
Situacion de los programas de control de la lepra en las Americas. Borges, M. V. (A)	334
The application of a health education model to obtain early and regular treatment of leprosy patients. Matthews, C. M. E. (A)	347
The possibility of leprosy eradication in Shandong Province by year 2000. Fan, Y.-L. and Zhao, T. (A)	333
Corticosteroids,	
Amoebic disease precipitated by corticosteroids prescribed for tuberculous pleural ef- fusions. Ratcliffe, G. E. (A)	731
Corynebacteria, leprosy derived (LDC),	
Comparative biochemical analysis of the genomes of leprosy associated bacteria (<i>M.</i> <i>leprae</i> , LDC and ADM). Coene, M., <i>et al.</i> (A)	320
Size and homology of the genomes of leprosy-derived corynebacteria and mycobacteria. Antoine, I., <i>et al.</i> (A)	142
Cuba,	
[A comparative study of epidemiologic surveys of the incidence of leprosy in the years 1980 to 1984 in the cities of 10 Octubre and Arroyo Naranjo (Cuba).] Alvarez Mesa, M., <i>et al.</i> (A)	586
Cultivation,	
Cultivation of <i>M. leprae</i> : a new approach. Bapat, C. V. (C)	874
<i>In vitro</i> cultivation of <i>M. leprae</i> under microaerophilic conditions. Ishaque, M. (A)	321
Investigations into cultivation of <i>M. leprae</i> under low oxygen tension. Ishaque, M. (C)	115

Cutaneous,

- A study of cutaneous lesions of leprosy on male genitalia. Arora, S. K., *et al.* (A) 894
- Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. McDougall, A. C. (C) 114
- Differential recognition of *Leishmania aethiopica* antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Akuffo, H. O., *et al.* (A) 727
- Disseminated cutaneous infection caused by *M. kansasii*: report of a case. Tseng, H. M., *et al.* (A) 732
- Drs. Jacob and Mathai reply (diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy). Jacob, M. and Mathai, R. (C) 114
- Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* (A) 733
- Morphometric study of stratum corneum in leprosy. Okhandiar, R. P., *et al.* (A) 710
- The reconstruction of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., *et al.* (A) 714
- Turn-over of stratum corneum in leprosy. Okhandiar, R. P., *et al.* (A) 139

Damien-Dutton Society,

- 1988 Damien-Dutton Award to Hermann Kober (S) 252

Dapsone (DDS) (see also Sulfones),

- Certain aspects of dapsone metabolism in leprosy patients as studied by high performance liquid chromatography (HPLC) and qualitative screening tests. Irudaya Raj, P. P., *et al.* (A) 129
- Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. THELEP Clinical Trials Subcommittee (A) 131
- Clofazimine and dapsone compliance in leprosy. Ellard, G. A., *et al.* (A) 128
- Double résistance RMP-dapsone dans 12 souches de *M. leprae* en Martinique: étude retrospective, analyse des causes et prospective. Constant-Desportes, M., *et al.* (A) 335
- Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* (A) 899
- Humoral immune responses in dapsone treated *M. leprae* infected mice. Srinivasan, P. and Rao, P. R. (A) 910
- Influence of acetylator phenotype of the leprosy patients on the emergence of dapsone resistant leprosy. Irudaya Raj, P. P., *et al.* (A) 129
- Influence of age, sex and body weight on the dapsone acetylation phenotype. Philip, P. A., *et al.* (A) 130
- Investigations into the haemolytic effects of dapsone therapy in leprosy patients. Balakrishnan, S., *et al.* (A) 707
- Long term follow up of PB patients treated with either a single dose of rifampicin (RMP) followed by one year of DDS (regimen A) or 10 weekly doses of RMP (regimen B). Janssens, L., *et al.* (A) 340
- N-Acetylation polymorphism of dapsone in a Japanese population. Horai, Y. and Ishizaki, T. (A) 567
- [Photodermatitis induced by DDS in a leprosy patient.] Fumey, S. M. (A) 567
- Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients. Garg, S. K., *et al.* (A) 708
- Relapse rates in paucibacillary leprosy—WHO regimen versus dapsone monotherapy. Jesudasan, K., *et al.* (A) 340
- Structure pharmacokinetic relationship in a series of dapsone derivatives. Visser, K., *et al.* (A) 317
- Survey of primary dapsone-resistant leprosy. Wang, H., *et al.* (A) 568
- The effect of treatment with rifampicine, chlofazimine and dapsone in multibacillary leprosy in the field for three years. Li, W.-Z., *et al.* (A) 341

Deformity,

- [A survey of deformity and disability among 1480 cases of leprosy.] Zheng, T., *et al.* (A) 726
- Etude epidemiologique des déformations chirurgicalement curables de 1059 patients hanseniens en zone rurale. Gaisne, E., *et al.* (A) 314
- [Investigation of deformity and disability in leprosy.] Zhao, X. (A) 148

Leprosy deformities. II. As parameters to monitor the effectivity of leprosy control programme. Mishra, B., <i>et al.</i> (A)	146
Monitoring of patient peripheral nerve status and deformity in Hansen's disease. Bell-Krotoski, J. (A)	337
Productivity loss due to deformity from leprosy in India. Max, E. and Shepard, D. S. (O)	476
[Survey of deformity and disability in leprosy.] Zhang, J. (A)	148
Deoxyfructoserotonin,	
DFS, an anti-leprosy drug without side effects. Ambrose, E. J., <i>et al.</i> (A)	315
La desoxyfructoserotonine: son effet therapeutique dans le traitement de la lèpre. Mester de Parajd, M., <i>et al.</i> (A)	893
Dermatology,	
A study of dermatological conditions in leprosy in-patients. Patki, A. H., <i>et al.</i> (A)	710
Dermatology and Leprosy Research Institute. (N)	119
The story of sulfones in tropical medicine and dermatology. Wozel, G. (A)	707
Dermatoglyphics,	
Dermatoglyphics in leprosy: (III) Creases of palm. Ghei, S. K., <i>et al.</i> (A)	709
[Generation of a linear discriminant function of dermatoglyphics for the detection of high risk groups in leprosy.] Goncalves, A., <i>et al.</i> (A)	723
DNA,	
Restriction map of mycobacteriophage D29 and its deletion mutant F5. Lazraq, R., <i>et al.</i> (A)	917
Dominican Republic,	
Sistema de lucha antileprosa en Republica Dominicana. Diaz, H. B., <i>et al.</i> (A)	322
Drugs (see also specific drugs),	
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. (A)	132
Comparative study of different drug compliance tests available in leprosy. Naik, S. S. and Sahasrabudhe, R. V. (A)	130
Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction. Kar, H. K. and Roy, R. G. (A)	133
Controlled clinical trial for evaluation of antimicrobial drug activity against <i>M. leprae</i> . Grosset, J. H. and Ji, B.-H. (E)	529
Correlations among naturally occurring resistances to antituberculosis drugs in <i>M. avium</i> complex strains. Tsukamura, M. and Miyachi, T. (A)	920
Current clinical status of uveitis in leprosy under various drug regimes. Samanta, S. K., <i>et al.</i> (A)	355
DFS, an anti-leprosy drug without side effects. Ambrose, E. J., <i>et al.</i> (A)	315
Direct antimicrobial drug susceptibility testing of <i>M. tuberculosis</i> by the radiometric method. Libonati, J. P., <i>et al.</i> (A)	592
Drug compliance among self-motivated leprosy patients. Girdhar, A., <i>et al.</i> (A)	567
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of <i>M. leprae</i> by Schwann cells <i>in vitro</i> . Chaudhury, A., <i>et al.</i> (A)	893
[Ethionamide in combined chemotherapy.] Carvalho Costa, I. M., <i>et al.</i> (A)	565
<i>In vitro</i> activity of ciprofloxacin in combination with standard antituberculous drugs against <i>M. tuberculosis</i> . Uttley, A. H. C. and Collins, C. H. (A)	151
<i>In vitro</i> screening of antileprosy drugs by mass spectrometric analysis of <i>M. leprae</i> . Lindner, B., <i>et al.</i> (A)	350
Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., <i>et al.</i> (A)	131
Measurement of ATP content of <i>M. leprae</i> —its application to the determination of viability and drug sensitivity screening. Katoch, V. M., <i>et al.</i> (A)	321
[Morphological characteristics of cell cultures from human and animal lepromas and the effect of antileprosy drugs on them.] Vishnevetsky, F. E., <i>et al.</i> (A)	909
<i>Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia,</i>	

<i>Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday</i> by the World Health Organization. (B)	122
Multiple drug therapy in Zimbabwe. Matemera, B. O. (A)	336
New experimental drugs for the treatment of tuberculosis. Parenti, F. (A)	730
Pharmacochemical aspects of leprosy; recent developments and prospects for new drugs. van Saane, P. and Timmerman, H. (A)	894
Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Mukhopadhyay, A., <i>et al.</i> (A)	918
<i>Report of Fifth Meeting Ad Hoc Drug Development Subgroup of the THELEP SWG.</i> . . (N)	886
Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on <i>M. avium</i> complex. Hoffner, S. E., <i>et al.</i> (A)	916
The bacteriological examination of slit-skin smears in leprosy control programmes using multiple drug therapy: a plea for radical changes in current operational methodology. Georgiev, G. D. and McDougall, A. C. (A)	570
The effect of anti-reactional drugs on complement components in the type II, erythema nodosum leprosum, reaction. Sehgal, V. N., <i>et al.</i> (A)	135
Electron microscopy (see also Ultrastructure),	
An electron microscopic study of lymphatics in the dermal lesions of human leprosy. Mukherjee, A., <i>et al.</i> (O)	506
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., <i>et al.</i> (A)	310
ELISA (enzyme-linked immunosorbent assay) tests,	
A competitive ELISA for the detection of mycobacterial antigen in tuberculosis exudates. Ramkisson, A., <i>et al.</i> (A)	730
An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., <i>et al.</i> (A)	304
[Assay of antibody level in sera of leprosy patients with <i>M. smegmatis</i> ELISA.] Wu, Q., <i>et al.</i> (A)	718
Detection of lepromatous leprosy patients shedding <i>M. leprae</i> in nasal droppings by enzyme immunoassay. Moudgil, K. D., <i>et al.</i> (A)	579
Detection of leprosy antigenuria through DOT-ELISA. Singh, N. B. and Choudhary, A. (A)	573
Evaluation of an enzyme immunoassay based on sonicate supernatant antigens of <i>Mycobacterium w</i> for immunodiagnosis of leprosy. Moudgil, K. D., <i>et al.</i> (A)	138
Evaluation of FLA-ABS, T/PG1-ELISA and their uses in immunoepidemiologic studies on leprosy. Wu, Q.-X., <i>et al.</i> (A)	305
Identification of mycobacterial antigens for "ELISA" serology in the diagnosis of leprosy and tuberculosis. Das, P. K., <i>et al.</i> (A)	898
Quantitative antibody ELISA for leprosy. Hasan, R., <i>et al.</i> (O)	766
Serodiagnostic potentialities of enzyme-linked immunosorbent assay (ELISA) using mannophosphoinositides of <i>M. tuberculosis</i> H37Rv. Mehta, P. K. and Khuller, G. K. (A)	593
Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Burgess, P. J., <i>et al.</i> (A)	144
Enzymes,	
Urinary excretion of renal brush-border enzymes in lepromatous leprosy—a preliminary investigation. Kohli, M., <i>et al.</i> (O)	20
Epidemiology,	
An epidemiological study on leprosy in southern Taiwan. Chou, P., <i>et al.</i> (A)	330
Comparative epidemiological and operational assessment of a vertical and an integrated leprosy control program. Parkhe, S. M., <i>et al.</i> (A)	330
Determination of sample sizes for epidemiological surveys using cluster sampling technique. Jeyaseelan, L. and Rao, P. S. S. (A)	723
Endemicity of leprosy and its control in Zhejiang Province. Chen, D. (A)	144
Enquetes d'évaluation par sondage de la prévalence de l'endemie lépreuse en Afrique Centrale. Joss, R., <i>et al.</i> (A)	323
Epidemiology of leprosy in tribals in Adhaura Plateau (India). Kaur, P., <i>et al.</i> (A)	587

Fit and analysis of the trend curve of leprosy epidemic. Pan, B., <i>et al.</i> (A)	587
Immuno-epidemiological studies of a hyperendemic pocket in a low endemic area. Yellapurkar, M. V. and Vaidya, M. C. (A)	332
Implications of genetics for the epidemiology and control of leprosy. Fine, P. E. M. . . . (A)	586
The characteristics and mode of detection of the new patients encountered in the leprosy endemic province of Van (Turkey) within the last five years. Saylan, T., <i>et al.</i> (A)	911
The epidemiology of leprosy in a high prevalence village in Papua New Guinea. Bag- shawe, A., <i>et al.</i> (A)	722
The rural-urban paradox in leprosy. Fine, P. E. M., <i>et al.</i> (A)	330
Use of soluble antigens in leprosy epidemiology. Gupte, M. D. and Anantharaman, D. S. (A)	577
Erythema nodosum leprosum (ENL),	
Changes in circulating levels of agalactosyl IgG during episodes of erythema nodosum leprosum. Rook, G. A. W., <i>et al.</i> (A)	312
Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction. Kar, H. K. and Roy, R. G. (A)	133
Comprehensive evaluation of complement components in the course of type I (lepra) and type II (ENL) reactions. Sehgal, V. N., <i>et al.</i> (A)	716
[Effects of clofazimine on the patients with ENL dependent upon corticosteroids.] Yu, X., <i>et al.</i> (A)	568
Leukemoid reaction in erythema nodosum leprosum in a leprosy patient. Chaudhary, S. D., <i>et al.</i> (A)	569
Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Dharma Rao, T. and Rao, P. R. (A)	133
Solubilization of preformed immune complexes in sera of lepromatous patients with erythema nodosum leprosum. Chakrabarty, A. K., <i>et al.</i> (A)	311
Vitiligo following type II lepra reaction. Pavithran, K. (A)	711
Erythromycin,	
Cure of bacille Calmette-Guérin vaccination abscesses with erythromycin. Murphy, P. M., <i>et al.</i> (A)	729
Escherichia coli,	
Expression in recombinant <i>E. coli</i> of biotinylated proteins of <i>M. leprae</i> . Moss, M. T. and Dale, J. W. (A)	327
Overproduction and purification of <i>M. leprae</i> 65 kD protein in <i>Escherichia coli</i> . Noma- guchi, H., <i>et al.</i> (A)	329
Overproduction, affinity purification and characterization of 65-kDa protein of <i>M. leprae</i> in <i>Escherichia coli</i> . Nomaguchi, H., <i>et al.</i> (O)	817
Selection of recombinant DNA clones expressing the 12K and 36K <i>M. leprae</i> antigens in <i>E. coli</i> K12. Hartskeerl, R. A., <i>et al.</i> (A)	328
Transformation of <i>M. smegmatis</i> with <i>Escherichia coli</i> plasmids carrying a selectable resistance marker. Zainuddin, Z. F., <i>et al.</i> (A)	720
Use of recombinant antigens expressed in <i>Escherichia coli</i> K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of <i>M. bovis</i> BCG. Thole, J. E. R., <i>et al.</i> (A)	717
Ethambutol,	
Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on <i>M. avium</i> complex. Hoffner, S. E., <i>et al.</i> (A)	916
Ethionamide,	
[Ethionamide in combined chemotherapy.] Carvalho Costa, I. M., <i>et al.</i> (A)	565
Ethiopia,	
<i>Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday</i> by the World Health Organization. (B)	122
Relationship of paralysis to age in leprosy patients in Ethiopia. Smith, V. B. and Ab- dulkadir, S. (A)	314

- Experimental leprosy,**
 Effect of ofloxacin on experimental leprosy. Kohsaka, K., *et al.* (A) 316
 Recent advances in experimental leprosy: a brief review. Job, C. K. and Hastings,
 R. C. (A) 721
 [Reproduction of experimental leprosy infection in mice with previously induced in-
 sufficiency of mononuclear phagocyte system.] Vishnevetsky, F. E., *et al.* (A) 910
 Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty man-
 gabey monkeys with experimental leprosy. Gormus, B. J., *et al.* (A) 309
 The nude mouse as an experimental lepromatous model (continued): the NSF/N nude
 mouse as a new model using the intra-upper lip inoculation method. Nakamura, K.
 and Yogi, Y. (A) 721
- Eye(s),**
 Current clinical status of uveitis in leprosy under various drug regimes. Samanta, S. K.,
et al. (A) 355
 Edge-light pupil cycle time in leprosy. Karacorlu, M. A., *et al.* (A) 355
 Eye lesions in leprosy. Soshamma, G. and Suryawanshi, N. (A) 896
 Intraocular pressure in Hansen's disease. Lewallen, S., *et al.* (A) 355
 Ocular complications of leprosy: methods for control. Courtright, P. and Johnson,
 C. J. (A) 354
 Ocular leprosy in the armadillo and man—a histopathological study. Jacob, M. (A) 355
 [Ocular leprosy—clinical statistics.] Watanabe, I., *et al.* (A) 573
 [Survey of eye diseases in leprosy patients.] Liu, Z., *et al.* (A) 134
 Tarsal strip procedure for surgical correction of lagophthalmos. Suryawanshi, N. (A) 356
 The eye in multidrug therapy. Rajan, M. A. (A) 355
 The protective effectiveness of methyl cellulose drops and conoid shields in the presence
 of lagophthalmos and corneal hypesthesia in ocular leprosy. Karacorlu, M. A., *et al.*
 (A) 354
 The results of a multicentre survey of the ocular complications of leprosy. ffytche, T. . . (A) 354
- FLA-ABS test,**
 Evaluation of FLA-ABS, T/PG1-ELISA and their uses in immunoepidemiologic studies
 on leprosy. Wu, Q.-X., *et al.* (A) 305
 Use of nonconventional antigen, *M. habana*, in detecting *M. leprae* antibodies from
 leprosy patients and contacts in FLA-ABS test. Rana, N. S., *et al.* (A) 580
- Foot,**
 Bacteriology of infected hands and feet in leprosy patients. Abdulkadir, S. (A) 708
 Bilateral involvement of sole and palm in leprosy; a case report. Chattopadhyay, S. P.,
et al. (A) 895
 Correction of severe foot deformities by a simple technique. Abram, G., *et al.* (A) 318
 Effect of rocker sole design on plantar forefoot pressures. Nawoczenski, D. A., *et al.* . . (A) 725
 Measurement of shock-waves during heel strike. Kahmann, L. R. M., *et al.* (A) 343
 Spina bifida occulta with atrophy of toes. Talwar, S. (A) 136
Peripheral Denervation of the Foot by Carl D. Enna. (B) 121
 Protective sensation in the foot in leprosy. Hammond, C. J. and Klenerman, P. (A) 570
 The neuropathic foot—a management scheme: a case report. Nawoczenski, D. A., *et al.*
 (A) 726
- Foot pad(s),**
 Comparison of *in vitro* Fc receptor assay with other methods including mouse foot pad
 method. Jagannathan, R., *et al.* (A) 321
 Correlation of *in vitro* Fc receptor assay with *in vivo* mouse foot pad method. Jagan-
 nathan, R., *et al.* (A) 584
 [Effect of removal of the popliteal ganglion on multiplication of *M. leprae* in the mouse
 foot-pad: preliminary report.] Moreno, O. S. and Silveira, J. R. (A) 143
 Mouse footpad pathogenicity of the chemoautotrophic nocardioform isolates from hu-
 man and mouse footpad leprosy tissues. Pal, N. K., *et al.* (A) 308
 Non-immune clearance of *M. leprae* from the footpads of *M. leprae*-infected, multidrug-
 treated nude mice. Chehl, S. K., *et al.* (A) 349
- Gambia,**
 Integrated leprosy control in the Gambia. Kinteh, S. B. and Bouchier, V. A. (A) 323

Genetics, bacterial,

- Development of genetic systems for the mycobacteria. Jacobs, W. R., Jr., *et al.* (A) 907
- Genetic relatedness among *M. paratuberculosis* and *M. avium* complex. Labidi, A. and Thoen, C. O. (A) 917
- Genetic relatedness among *M. tuberculosis* and *M. bovis*. Labidi, A. and Thoen, C. O. (A) 917
- Genetic relatedness among *M. leprae*, *M. tuberculosis*, and candidate leprosy vaccine strains determined by DNA hybridization: identification of an *M. leprae*-specific repetitive sequence. Grosskinsky, C. M., *et al.* (A) 719
- Use of DNA probes to investigate the genetics of *M. leprae*. McFadden, J., *et al.* (A) 328

Genetics, human,

- A test statistic for the affected-sib-set method. Lange, K. (A) 146
- Fiftieth anniversary of the "N-Factor/Hansen-aneergic fringe" hypothesis for hanseniasis. Rotberg, A. (C) 864
- Genetic susceptibility to leprosy on a Caribbean island: linkage analysis with five markers. Abel, K., *et al.* (O) 465
- Implications of genetics for the epidemiology and control of leprosy. Fine, P. E. M. (A) 586

Genome,

- Comparative biochemical analysis of the genomes of leprosy associated bacteria (*M. leprae*, LDC and ADM). Coene, M., *et al.* (A) 320
- Construction of genomic library of *M. leprae* gene and its expression in *Streptomyces lividans*. Makino, M., *et al.* (A) 328
- Genomic and amino acid sequence of the *M. leprae* 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., *et al.* (A) 318
- Size and homology of the genomes of leprosy-derived corynebacteria, *M. leprae*, and other corynebacteria and mycobacteria. Antoine, I., *et al.* (A) 142

Germany, Federal Republic of,

- Hermann Kober receives 1988 Damien-Dutton Award. (S) 252

Granuloma(s),

- Identification of subpopulations of CD4+ and CD8+ T cells in leprosy granulomas. Rea, T. H. and Modlin, R. L. (A) 327
- Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., *et al.* (A) 310
- Immunopathology of leprosy granulomas. Modlin, R. L. and Rea, T. H. (A) 902
- Tubercloid granuloma in a clinically normal looking skin. Haldar, S. R., *et al.* (A) 133

Guadeloupe,

- Leprosy reactions and disabilities in patients treated with daily MDT in New Caledonia, French Polynesia and Guadeloupe. Bobin, P., *et al.* (A) 313
- Results after 8 years of a daily multidrug therapy for leprosy patients in Guadeloupe, New Caledonia and Polynesia. Cartel, J. L., *et al.* (A) 335

Haiti,

- Is prior mycobacterial infection a common predisposing factor to AIDS in Haitians and Africans? Lamoureux, G., *et al.* (A) 592
- Prévalence et évolution de l'infection au virus humain d'immunodéficience (VIH) chez les lepreux en Haiti. Pean, C., *et al.* (A) 306

Hand(s),

- A hand biomechanics workstation. Thompson, D. E., *et al.* (A) 726
- A modification of the surgical correction of the thumb—a long term follow up. Beine, A. O., *et al.* (A) 725
- Bacteriology of infected hands and feet in leprosy patients. Abdulkadir, S. (A) 708
- Bilateral involvement of sole and palm in leprosy; a case report. Chattopadhyay, S. P., *et al.* (A) 895
- Neurolysis: an approach to leprosy claw hand. Chattopadhyay, S. P., *et al.* (A) 588
- Peripheral Denervation of the Hand* by Carl D. Enna. (B) 121

Hawaii,		
Hansen's disease in Hawaii; current status. Frankel, R. I. (A)		587
Hepatitis,		
Leprosy and hepatitis B surface antigen. Vaishnavi, C., <i>et al.</i> (A)		896
Serological pattern of hepatitis B virus markers (HBsAg, anti-HBs, IgM anti-HBc and HBV specific DNA polymerase) in leprosy patients. Moudgil, K. D., <i>et al.</i> (A)		710
Histoid leprosy,		
Multiple neurofibromatosis with histoid leprosy. Thomas, J., <i>et al.</i> (C)		695
Histopathology,		
A comparison of sensory loss tests and histopathology in the diagnosis of leprosy. Ponnighaus, J. M. and Fine, P. E. M. (A)		896
Histology and fine structure of lepromatous nerves, before and after treatment. Dastur, D. K., <i>et al.</i> (A)		337
New findings in the histopathology of indeterminate leprosy. Ravindranathan, O. and Sarojini, P. A. (A)		345
History of leprosy,		
[On the relation between the ancient poem "Fu Yi" and leprosy.] Liang, Z., and Ma, X. (A)		127
Three times, three places, three authors, and one perspective on leprosy in medieval and early modern Europe. Ell, S. R. (E)		825
HLA,		
A <i>M. leprae</i> -specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Anderson, D. C., <i>et al.</i> (A)		136
Association of tuberculosis and <i>M. tuberculosis</i> -specific antibody levels with HLA. Bothamley, G. H., <i>et al.</i> (A)		727
HLA-DQ molecules may be products of an immune suppression gene responsible for <i>M. leprae</i> -specific nonresponsiveness. Lei, S.-G. and de Vries, R. R. P. (C)		554
[HLA-DR phenotype and B/DR haplotype in patients with sarcoidosis.] Ketova, N. A. (A)		729
HLA-DR, -DQ DNA genotyping and T-cell receptor RFLPs in leprosy. Jazwinska, E. C. and Serjeantson, S. W. (A)		145
HLA-DR-restricted antigen-induced proliferation and cytotoxicity mediated by CD4+ T-cell clones from subjects vaccinated with killed <i>M. leprae</i> . Mustafa, A. S. and Qvigstad, E. (O)		1
Regulation of T cell responsiveness against mycobacterial antigens by HLA class 2 immune response genes. de Vries, R. R. P. (A)		713
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., <i>et al.</i> (A)		144
Hypersensitivity,		
Induction of the late hypersensitivity reaction to DNCB in patients with different clinical forms of hanseniasis in Brazil. Azulay, R. D. (A)		310
The role of CD8+ cells in resistance and delayed hypersensitivity reactions in <i>M. lepraemurium</i> infection. Curtis, J., <i>et al.</i> (A)		308
IMMLEP (WHO Immunology of Leprosy Scientific Working Group),		
The contribution of IMMLEP to recent advances in immunology and molecular biology of <i>M. leprae</i> . Engers, H. D., <i>et al.</i> (A)		326
Immune complexes,		
Effects of <i>in vitro</i> formed immune complexes on macrophage functions of <i>M. leprae</i> infected mice. Vaishnavi, C., <i>et al.</i> (A)		141
Influence of <i>in vitro</i> administered immune complexes on serum levels of complement and circulating immune complexes in <i>M. leprae</i> infected mice. Vaishnavi, C., <i>et al.</i> (A)		586
Persistent reduced solubilization of immune complexes in leprosy patients with reactions. Ramu, G., <i>et al.</i> (A)		312
Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Dharma Rao, T. and Rao, P. R. (A)		133
Solubilization of preformed immune complexes in sera of lepromatous patients with erythema nodosum leprosum. Chakrabarty, A. K., <i>et al.</i> (A)		311

Immune responses,

- Activation of $\gamma\delta$ T cells in the primary immune response to *M. tuberculosis*. Janis, E. M., *et al.* (A) 900
- Comparison of cell-mediated immune responses to *M. leprae* in mice following successful infection with *M. leprae* or immunization with killed *M. leprae*. Mshana, R. N., *et al.* (A) 309
- Humoral immune responses in dapsone treated *M. leprae* infected mice. Srinivasan, P. and Rao, P. R. (A) 910
- International Conference on Molecular Aspects of Immune Response and Infectious Diseases. (N) 558
- Macrophage mediated immune responses in the sciatic nerves of *M. leprae* infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., *et al.* (A) 310
- Regulation of T cell responsiveness against mycobacterial antigens by HLA class 2 immune response genes. de Vries, R. R. P. (A) 713
- Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., *et al.* (A) 582
- The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* (A) 577
- The role of the 65-kDa protein in the immune response to *M. leprae*. Colston, M. J., *et al.* (A) 325

Immunoglobulins,

- Changes in circulating levels of agalactosyl IgG during episodes of erythema nodosum leprosum. Rook, G. A. W., *et al.* (A) 312
- [Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., *et al.* (A) 918
- Comparative studies of serum IgA1, IgA2 and IgM against phenolic glycolipid I in leprosy patients and contacts. Chujor, C. S. N., *et al.* (A) 304
- Conformational changes in the IgG molecule of lepromatous sera using laser Raman spectroscopy. Kumar, P., *et al.* (A) 138
- Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., *et al.* (A) 899
- Glomerular immunoglobulin deposition in the absence of tissue damage in murine leprosy. Rojas-Espinosa, O., *et al.* (C) 879

Immunology,

- A clinical, immunological and histological study in neuritic leprosy patients. Girdhar, B. K., *et al.* (A) 338
- [Current thoughts on the immunology of leprosy.] Sagaro Delgado, B., *et al.* (A) 580
- Expression, purification and immunologic activity of recombinant 65-kilodalton protein of *M. leprae*. Gillis, T. P. and Williams, D. L. (A) 328
- Immuno-epidemiological studies of a hyperendemic pocket in a low endemic area. Yellapurkar, M. V. and Vaidya, M. C. (A) 332
- Immunological heterogeneity in type 1 reactions. Laal, S., *et al.* (A) 311
- Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., *et al.* (A) 905
- Immunological tools in leprosy control. Fine, P. E. M. (E) 671
- Indications that early events causing nerve damage in leprosy may not be immunologically mediated. Antia, N. H., *et al.* (A) 337
- Molecular study of the T cell repertoire in family contacts and patients with leprosy. Mendez-Samperio, P., *et al.* (A) 902
- Mucosal immunity in leprosy. Cree, I. A., *et al.* (A) 381
- Rapid and precise diagnosis of atypical mycobacterial infection by chemotaxonomical and immunological methods. Ikawa, H., *et al.* (A) 916
- Studies of a common idiotype PR4 in autoimmune rheumatic disease. Williams, W., *et al.* (A) 581
- The contribution of IMMLEP to recent advances in immunology and molecular biology of *M. leprae*. Engers, H. D., *et al.* (A) 326
- Tumor necrosis factor in leprosy patients. Silva, C. L. and Foss, N. T. (A) 712

Immunotherapy,

- Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments. Katoch, K., *et al.* (A) 900

Indeterminate leprosy,

- Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* (A) 899
- Indeterminate leprosy in a population survey and in the subsequent follow-up of children. Bechelli, L. M. (A) 305
- Indeterminate leprosy; twenty year study—histologic observations. Abalos, R. M. (A) 344
- Is the proportion of the new indeterminate leprosy cases dependent on the screening interval? Worth, R. M., *et al.* (A) 308
- New findings in the histopathology of indeterminate leprosy. Ravindranathan, O. and Sarojini, P. A. (A) 345

India,

- A pilot study of three potential vaccines for leprosy in Bombay school children. Stanford, J. L., *et al.* (A) 350
- A pilot study of three potential vaccines for leprosy in Bombay. Ganapati, R., *et al.* ... (O) 33
- Bombay Leprosy Project 1989 Antileprosy Week celebrations. (N) 700
- Changing Face of Leprosy; a film. (N) 884
- Changing picture of leprosy in North Arcot District, Tamil Nadu, after M.D.T. Ekambaram, V. and Rao, M. K. (A) 708
- Childhood leprosy in Bombay: a clinico-epidemiological study. Nadkarni, N. J., *et al.* (A) 146
- Dermatology and Leprosy Research Institute. (N) 119
- Dr. Claire Vellut honored. (N) 884
- Dr. Joseph A. Ponniah is new Director of SLR&TC, Karigiri. (N) 884
- Dr. Rajendra Prasad Gold Medal to Shri R. S. Mani. (N) 885
- Epidemiology of leprosy in tribals in Adhaura Plateau. Kaur, P., *et al.* (A) 587
- Experiences with health education strategy being followed under National Leprosy Eradication Programme in India. Dharmshaktu, N. S. and Mittal, B. N. (A) 347
- Factors influencing voluntary reporting of leprosy patients in Madras, an urban metropolitan city in India. Lobo, D., *et al.* (A) 347
- XV IAL Conference and new officers. (N) 119
- Impact of multidrug therapy on leprosy in Baroda District (Gujarat). Chopra, N. K., *et al.* (A) 892
- Indian Association of Leprologists (IAL). (N) 885
- Intraspecies differentiation of strains of *M. tuberculosis* obtained from Czechoslovakian, Mongolian and South Indian patients. Venkataraman, P., *et al.* (A) 596
- JALMA Trust Fund Oration Award to Virendra N. Sehgal. (N) 700
- Karigiri Video teaching/training materials. (N) 701
- Leprosy control in a Bombay slum—a general assessment. Goyder, E. C. (A) 145
- Leprosy teaching in medical colleges in Bombay—a questionnaire study. Sheela, G. R., *et al.* (A) 890
- Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday* by the World Health Organization. (B) 122
- National Leprosy Eradication Commission reconstituted. (N) 885
- Observance of Antileprosy Day 30 January 1989. (N) 700
- Occlusive hydrocolloid dressings applied to chronic neuropathic ulcers. A study of efficacy in patients in a rural south Indian hospital. Mumford, J. W. and Mumford, S. P. (A) 148
- Poona District Leprosy Committee Annual Report 1987–1988. (N) 701
- Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988.* (B) 124
- Productivity loss due to deformity from leprosy in India. Max, E. and Shepard, D. S. (O) 476
- XVI All India Leprosy Workers Conference 1989. (N) 702
- XVI Biennial IAL Conference. (N) 703
- Skin test studies on close contacts of leprosy patients in India. Lord, R., *et al.* (O) 801
- State Leprosy Conference 1989. (N) 886

Surveillance and relapse rates after MDT in over 700 paucibacillary leprosy cases—a two year follow up at Purulia, India. Casablanca, M. N. and Nayagam, A. S. (A)	339
Trend of leprosy in Sevagram control unit (Maharashtra, India). Tare, S. P. (A)	332
Indonesia,	
Sample surveys in leprosy: milestone for Indonesia. Louhenapessy, A. A., <i>et al.</i> (A)	332
Surabaya urban leprosy control program. Sastrowidjojo, H., <i>et al.</i> (A)	333
WHO MDT regime in Molucas Province (East Indonesia), January 1982–December 1987. Louhenapessy, A. and Sugiene, R. (A)	336
Interferon,	
[Correlation between skin tests and the production of gamma-interferon in patients with hanseniasis.] Suso, L., <i>et al.</i> (A)	905
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Sibley, L. D., <i>et al.</i> (A)	140
Interleukin(s),	
[Determination of ability of producing IL-2 and activity of NK in multibacillary leprosy.]	
Xiong, S., <i>et al.</i> (A)	719
Interleukin-2 receptors in the sera of leprosy patients. Ganguly, N. K., <i>et al.</i> (C)	870
Intradermal IL-2 injections enhance <i>in vitro</i> responses to mycobacterial antigens in lepromatous leprosy patients. Converse, P., <i>et al.</i> (A)	325
Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Brown, A. R., <i>et al.</i> (A)	913
The reconstruction of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., <i>et al.</i> (A)	714
INTERNATIONAL JOURNAL OF LEPROSY (IJL),	
Author Index to Volume 57. (–)	167
Reviewers for Volume 57. (–)	922
Statement of financial condition. (–)	923
Statement of ownership, management, and circulation. (–)	926
Subject Index to Volume 57. (–)	178
The 1988 JOURNAL—a continuing perspective. Hastings, R. C. (E)	82
International Leprosy Association (ILA),	
List of Members (–)	153
Minutes of the Council meeting, 11 September 1988 (S)	236
Officers and Councillors (–)	152
International Leprosy Congress, XIII,	
Participants (S)	239
Pre-Congress Workshop Committees' reports (S)	275
Transactions (S)	229
Iran,	
A comparison of three potential vaccines for leprosy carried out in 59 villages in the Ahar Valley of eastern Azerbaijan, Iran. Ghazi-Saidi, K., <i>et al.</i> (A)	350
A policy for enhancing protective immunity in close contacts of leprosy patients developed in the Islamic Republic of Iran. Dowlati, Y., <i>et al.</i> (A)	349
Do environmental mycobacteria influence the distribution of disease in the leprosy spectrum? Bacteriological and skin test studies carried out in Iran. Velayati, A., <i>et al.</i> (A)	320
Italy,	
International Conference on Molecular Aspects of Immune Response and Infectious Diseases. (N)	558
Ivory Coast,	
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., <i>et al.</i> (A)	317
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): II. Biological results. Grosset, J., <i>et al.</i> (A)	316

Japan,

- Leydig cells observed in autopsy cases of the national leprosarium, Okukomyoen. Obara, A., *et al.* (A) 345
- N-Acetylation polymorphism of dapsone in a Japanese population. Horai, Y. and Ishizaki, T. (A) 567

Korea,

- An analysis of pulmonary tuberculosis data in Taiwan and Korea. Schulzer, M., *et al.* (A) 151
- Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* (A) 339

Kuwait,

- Recognition of a category of responders to group ii, slow-grower associated, antigens amongst Kuwaiti senior school children, using a statistical model. McManus, I. C., *et al.* (A) 592

Lactate dehydrogenase,

- Lactate dehydrogenase isoenzymes in leprosy patients on multidrug therapy—a preliminary report. Dhandayuthapani, S. and Bhatia, V. N. (A) 132
- Serum lactate dehydrogenase in murine leprosy: source and isozymes. Luna Herrera, J. and Rojas-Espinosa, O. (O) 641

Lepromatous leprosy,

- A comparative evaluation of serological assays for lepromatous leprosy. Mwantha, J., *et al.* (A) 138
- A florid case of borderline-lepromatous leprosy. Raman, J. and Fisher, D. (A) 896
- A report of six cases of histoid variety of lepromatous leprosy in children. Mohan, L., *et al.* (A) 710
- Detection of lepromatous leprosy patients shedding *M. leprae* in nasal droppings by enzyme immunoassay. Moudgil, K. D., *et al.* (A) 579
- Estimation of high density lipoprotein cholesterol in the diagnosis of lepromatous leprosy. Kumar, N., *et al.* (A) 571
- Evidence that *M. leprae* specific helper T cells exist in lepromatous leprosy patients. Gill, H. K., *et al.* (A) 319
- Facies leprosa*: some recent observations in patients with lepromatous leprosy in Malaysia. Subramaniam, K. and Marks, S. C., Jr. (A) 315
- Field trials of combined therapy in lepromatous leprosy. Vijayakumaran, P., *et al.* (A) 337
- Hyper-eosinophilic syndrome with lepromatous leprosy. Mehrotra, S. D., *et al.* (A) 895
- Immunotherapy of treated BL/LL cases with BCG: histopathological, immunohistological and bacteriological assessments. Katoch, K., *et al.* (A) 900
- Intradermal IL-2 injections enhance *in vitro* responses to mycobacterial antigens in lepromatous leprosy patients. Converse, P., *et al.* (A) 325
- Local immunomodulation with dinitrochlorobenzene in patients with lepromatous leprosy: immunohistological investigations. Volc-Platzer, B., *et al.* (A) 351
- Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* (A) 346
- Maxillary antrum in lepromatous leprosy (antoscopic study). Soni, N. K. (A) 314
- Lèpre lépromateuse: arguments cliniques et électrophysiologiques en faveur d'une multinévrite axonale. Tzourio, C., *et al.* (A) 339
- Mechanisms of *M. leprae*-specific T-cell deficiency in lepromatous leprosy. Bach, M.-A. and Launois, P. (A) 574
- Multicentric reticulohistiocytosis masquerading as lepromatous leprosy. Razak, E. M. A., *et al.* (A) 572
- [Pathologic changes and bacillation of blood vessels in LL and BL leprosy.] Liu, J., *et al.* (A) 578
- Presence of *M. leprae*-reactive lymphocytes in lymph nodes of lepromatous leprosy patients. Desai, S. D., *et al.* (A) 137
- Radiological study of the paranasal sinuses in lepromatous leprosy. Soni, N. K. (A) 136
- Reduced numbers of Leu 8(+) cells in peripheral blood of lepromatous leprosy patients (LL). Sasiain, M. de C., *et al.* (A) 325

Reduced suppressor cell response to <i>M. leprae</i> in lepromatous leprosy. Sasiain, M. del C., <i>et al.</i> (A)	715
[Secondary amyloidosis as a consequence of inadequate treatment in a lepromatous leprosy patient.] Montserrat Perez and Algaba, F. (A)	134
Single lesion subpolar lepromatous leprosy and its possible mode of origin. Job, C. K., <i>et al.</i> (O)	12
Survival of <i>Staphylococcus epidermidis</i> on the skin of patients with lepromatous leprosy. Kumar, B., <i>et al.</i> (A)	134
Tetanus in patients with lepromatous leprosy (I). Anilkumar, G., <i>et al.</i> (A)	132
The high prevalence of testicular involvement in lepromatous (LL) as compared to borderline lepromatous (BL) leprosy patients. Gebhard, J. F. and Rea, T. H. (A)	344
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., <i>et al.</i> (A)	144
Trial to determine the capacity of several vaccines to produce skin-test reactivity to a soluble <i>M. leprae</i> antigen in treated smear-negative patients with lepromatous leprosy. Fajardo, T. T., <i>et al.</i> (A)	318
Tuberculoid relapse in lepromatous leprosy. Waters, M. F. R. and Ridley, D. S. (A)	307
Ultrastructural studies on peripheral nerves in lepromatous leprosy patients. Kumar, V., <i>et al.</i> (A)	138
Urinary excretion of renal brush-border enzymes in lepromatous leprosy—a preliminary investigation. Kohli, M., <i>et al.</i> (O)	20
Lepromin,	
A critique on the interpretation of the lepromin reaction using heat-killed <i>M. leprae</i> vaccine. Mistry, N. F. and Antia, N. H. (C)	110
Identification of "high risk group" of leprosy in children using serological and lepromin test: a preliminary report. Naik, S. S., <i>et al.</i> (A)	910
Lepromin conversion induced by a "subunit" vaccine from ICRC bacilli. Bhatki, W. S., <i>et al.</i> (A)	136
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., <i>et al.</i> (A)	311
PGL-I independence of the lepromin (Mitsuda) reaction in pre-sensitized guinea pigs. Krotoski, W. A., <i>et al.</i> (A)	309
Relative cross reactivity of habanin, lepromin and tuberculin in guinea pigs sensitized with homologous and heterologous mycobacteria. Singh, N. B., <i>et al.</i> (A)	140
Reply by Gill, Mustafa and Godal (a critique on the interpretation of the lepromin reaction using heat-killed <i>M. leprae</i> vaccine). Gill, H. K., <i>et al.</i> (C)	112
Ten-year study of lepromin response in child contacts of leprosy patients. Ramu, G. . . (A)	715
The relationship between reactivities to lepromin A and soluble protein antigen of <i>M. leprae</i> and tuberculin. Pemajayantha, V., <i>et al.</i> (A)	579
Un traitement logique des névrites lépreuses tuberculoides et borderline aigues ou subaigues: la désensibilisation progressive a la lépromine. Saint-André, P., <i>et al.</i> . . . (A)	339
Lesion(s),	
A study of cutaneous lesions of leprosy on male genitalia. Arora, S. K., <i>et al.</i> (A)	894
A study of palmo-plantar lesions in leprosy: a preliminary report. Arora, S. K., <i>et al.</i> . . (A)	894
An electron microscopic study of lymphatics in the dermal lesions of human leprosy. Mukherjee, A., <i>et al.</i> (O)	506
Assessment of histological features in leprosy lesions by histometry. Cree, I. A. and Beck, J. S. (A)	576
Correlation of clinical and histopathologic features in untreated macular lesions of leprosy—a study of 100 cases. Sheno, S. D. and Siddappa, K. (A)	135
Evolution of leprosy lesions in man. Chacko, C. J. G. (A)	344
Eye lesions in leprosy. Soshamma, G. and Suryawanshi, N. (A)	896
Multibacillary lesions in nerves of patients with primary neuritic leprosy. Jacob, M. and Mathai, R. (A)	338
Relationships between oro-facial lesions, mutilations and periodontal status in leprosy patients in Lo-Sheng Sanatorium at Taiwan. Wong, M.-Y. and Chang, W.-K. (A)	897
Single lesion subpolar lepromatous leprosy and its possible mode of origin. Job, C. K., <i>et al.</i> (O)	12
Site of early lesions in leprosy. Mathur, D., <i>et al.</i> (A)	306

- Skin lesion in strain 13 guinea pig induced by a human non-myelin antigen in dorsal roots. Crawford, C. L., *et al.* (A) 308
- The anatomical distribution of single leprosy lesions in an African population, and its implications for the pathogenesis of leprosy. Ponnighaus, J. M., *et al.* (A) 307
- Leukocyte(s),**
- Leucocytic alkaline phosphatase activity, marker of evolution in leprosy? Guillet, G., *et al.* (A) 133
- Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* (A) 733
- Lipid,**
- Methionine as methyl-group donor in the synthesis of *M. avium* envelope lipids, and its inhibition by DL-ethionine, D-norleucine and DL-norleucine. David, H. L., *et al.* (A) 914
- Studies on lipids in mycobacterial cell wall: their important structure and function relating to pathogenicity and their biological activity. Bera, A. and Banerjee, A. (A) 905
- Lipoarabinomannan (LAM),**
- Lipoarabinomannan and lipomannan. Hunter, S. W. and Brennan, P. J. (A) 321
- Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Sibley, L. D., *et al.* (A) 140
- Use of an antigen-capture assay for characterization of monoclonal antibodies to mycobacterial lipoarabinomannan. Khanolkar, S. R., *et al.* (A) 901
- Lipoprotein,**
- Estimation of high density lipoprotein cholesterol in the diagnosis of lepromatous leprosy. Kumar, N., *et al.* (A) 571
- Liver,**
- A study of incidence of Australia antigen and derangements in liver function tests in leprosy. Nayak, K. C., *et al.* (A) 710
- Lucio leprosy,**
- Contemplative immune mechanism of Lucio phenomenon and its global status. Sehgal, V. N., *et al.* (A) 135
- Lupus,**
- Mononuclear leucocyte function in patients with lichen planus and cutaneous lupus erythematosus during chemotherapy with clofazimine. Zeis, B. M., *et al.* (A) 733
- Lymph node(s), lymphatics,**
- An electron microscopic study of lymphatics in the dermal lesions of human leprosy. Mukherjee, A., *et al.* (O) 506
- Lymph node studies in 30 necropsies of leprosy patients. Fleury, R. N. and Opromolla, D. (A) 344
- Presence of *M. leprae*-reactive lymphocytes in lymph nodes of lepromatous leprosy patients. Desai, S. D., *et al.* (A) 137
- Lymphocyte(s),**
- [Changes in the system of T-lymphocyte cyclic nucleotides in animals with experimental tuberculosis.] Kostromin, A. P., *et al.* (A) 591
- Characterization of *M. leprae* cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., *et al.* (A) 715
- Differential recognition of *Leishmania aethiopica* antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Akuffo, H. O., *et al.* (A) 727
- Effect of *M. leprae*-infected Schwann cells and their supernatant on lymphocyte neuroglia interaction. Mehta, R., *et al.* (A) 902
- Glucocorticoid receptor and lymphocytes in leprosy. Sheriff, S., *et al.* (A) 313
- Identification of mycobacterial antigens recognized by T lymphocytes. Lamb, J. R., *et al.* (A) 714
- Immunohistologic pattern of the portal T-lymphocyte infiltration in hepatic allograft rejection. Perkins, J. D., *et al.* (A) 918
- Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., *et al.* (A) 311

Lymphocytotoxins in leprosy. Kaur, I., <i>et al.</i> (A)	900
Presence of <i>M. leprae</i> -reactive lymphocytes in lymph nodes of lepromatous leprosy patients. Desai, S. D., <i>et al.</i> (A)	137
T lymphocytes, mononuclear phagocytes, Schwann cells and <i>M. leprae</i> . Kaufmann, S. H. E., <i>et al.</i> (A)	900
Macrophage(s),	
Aggregation phenomenon of cultivated blood macrophages isolated from leprosy patients. Yamagami, A., <i>et al.</i> (C)	873
Bacterial antigen processing in macrophages infected with the obligate intracellular bacterium, <i>M. avium</i> . de Chastellier, C. and Lang, T. (A)	914
Comparative intracellular growth of difficult-to-grow and other mycobacteria in a macrophage cell line. Rastogi, N., <i>et al.</i> (A)	920
Correlation between macrophage activation and bactericidal function of <i>M. leprae</i> antigen presentation in macrophages of leprosy patients and normal individuals. Desai, S. D., <i>et al.</i> (A)	712
Effects of <i>in vitro</i> formed immune complexes on macrophage functions of <i>M. leprae</i> infected mice. Vaishnavi, C., <i>et al.</i> (A)	141
Evidence that host-recycling of <i>M. avium</i> preserves its ability to hinder macrophage killing functions. Frehel, C., <i>et al.</i> (A)	915
Infection with live mycobacteria inhibits <i>in vitro</i> detection of Ia antigen on macrophages. Mshana, R. N., <i>et al.</i> (A)	150
Macrophage activity in resistant and susceptible mouse strains infected with <i>M. lepraemurium</i> . Brett, S. J. and Butler, R. (A)	589
Macrophage mediated immune responses in the sciatic nerves of <i>M. leprae</i> infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., <i>et al.</i> (A)	310
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Sibley, L. D., <i>et al.</i> (A)	140
Phagosome-lysosome fusions in macrophages infected with <i>M. avium</i> : role of mycosides-C and other cell surface components. Frehel, C. and Rastogi, N. (A)	915
Purification of <i>M. leprae</i> with special reference to the effects of purified <i>M. leprae</i> vaccines and host macrophage cell functions. Saito, H., <i>et al.</i> (A)	904
Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Mukhopadhyay, A., <i>et al.</i> (A)	918
Resistance of <i>M. avium</i> to microbicidal activities in bone-marrow macrophages from naturally susceptible (C57BL/6) and naturally resistant (DBA-2) mice. Rastogi, N. and Frehel, C. (A)	920
Selective coating of <i>M. leprae</i> surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in <i>M. leprae</i> -infected macrophages. Rastogi, N. and Frehel, C. (A)	326
The effect of clofazimine in cell mediated immunity: interference with antigen processing and presentation by macrophages. Brown, L. M., <i>et al.</i> (A)	315
The effect of phenolic glycolipid-I from <i>M. leprae</i> on the antimicrobial activity of human macrophages. Neill, M. A. and Klebanoff, S. J. (A)	139
The macrophage in leprosy: a review on the current status. Birdi, T. J. and Antia, N. H. (E)	511
Malawi,	
A new concept of staging paucibacillary leprosy and its application to the analysis of post-treatment results of a MDT study in Malawi. Boerrigter, G. and Ponnighaus, J. M. (A)	306
Disabilities in leprosy patients ascertained in a total population survey in Karonga District, northern Malawi. Ponnighaus, I. M., <i>et al.</i> (A)	314
Leprosy in Malawi. 1. Sensitivity and specificity of the diagnosis and the search for risk factors for leprosy. Ponnighaus, J. M. and Fine, P. E. M. (A)	572
Leprosy in Malawi. 2. Background, design and prospects of the Karonga Prevention Trial, a leprosy vaccine trial in northern Malawi. Fine, P. E. M. and Ponnighaus, J. M. (A)	586
<i>Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia,</i>	

<i>Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday</i> by the World Health Organization. (B)	122
The distribution and implications of BCG scars in northern Malawi. Fine, P. E. M., <i>et al.</i> (A)	728
Martinique,	
Double résistance RMP-dapsone dans 12 souches de <i>M. leprae</i> en Martinique: étude rétrospective, analyse des causes et prospective. Constant-Desportes, M., <i>et al.</i> (A)	335
Metabolism,	
Certain aspects of dapsone metabolism in leprosy patients as studied by high performance liquid chromatography (HPLC) and qualitative screening tests. Irudaya Raj, P. P., <i>et al.</i> (A)	129
Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., <i>et al.</i> . . (A)	594
Metabolism in <i>M. leprae</i> , <i>M. tuberculosis</i> and other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. (A)	143
Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients. Garg, S. K., <i>et al.</i> (A)	708
Mice, murine,	
A histopathological study of pulmonary infection of mice with <i>M. lepraemurium</i> . Ha, D. K. K., <i>et al.</i> (A)	590
Amikacin, ciprofloxacin, and imipenem treatment for disseminated <i>M. avium</i> complex infection of beige mice. Inderlied, C. B., <i>et al.</i> (A)	591
Characteristics of the multiplication of dapsone-resistant strains of <i>M. leprae</i> in mice. THELEP Clinical Trials Subcommittee (A)	131
Comparison of cell-mediated immune responses to <i>M. leprae</i> in mice following successful infection with <i>M. leprae</i> or immunization with killed <i>M. leprae</i> . Mshana, R. N., <i>et al.</i> (A)	309
[Development of experimental infection with <i>M. lepraemurium</i> in two strains of mice.] Roggero, E., <i>et al.</i> (A)	731
Effect of suppressor cells on antibody producing cells in mice infected with <i>M. leprae</i> . Vaishnavi, C., <i>et al.</i> (A)	718
Effects of <i>in vitro</i> formed immune complexes on macrophage functions of <i>M. leprae</i> infected mice. Vaishnavi, C., <i>et al.</i> (A)	141
Evaluation of the efficacy of candidate vaccines against <i>M. leprae</i> infection in mice. Sreevatsa and Desikan, K. V. (A)	141
Evaluation of the efficacy of candidate vaccines against <i>M. leprae</i> infection in mice. Desikan, K. V. and Sreevatsa (A)	349
Evidence for phagosome-lysosome fusion in <i>M. leprae</i> -infected murine Schwann cells. Steinhoff, U., <i>et al.</i> (A)	717
Glomerular immunoglobulin deposition in the absence of tissue damage in murine leprosy. Rojas-Espinosa, O., <i>et al.</i> (C)	879
Humoral immune responses in dapsone treated <i>M. leprae</i> infected mice. Srinivasan, P. and Rao, P. R. (A)	910
Influence of <i>in vitro</i> administered immune complexes on serum levels of complement and circulating immune complexes in <i>M. leprae</i> infected mice. Vaishnavi, C., <i>et al.</i> (A)	586
Limiting dilution of murine T cell response to mycobacterial antigens. Launois, P., <i>et al.</i> (A)	901
Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., <i>et al.</i> . . (A)	594
Macrophage activity in resistant and susceptible mouse strains infected with <i>M. lepraemurium</i> . Brett, S. J. and Butler, R. (A)	589
Pefloxacin and ofloxacin activities against <i>M. leprae</i> in the mouse. Guelpa-Lauras, C.-C., <i>et al.</i> (A)	316
Protection of mice by vaccines from cell walls of <i>M. leprae</i> . Gelber, R., <i>et al.</i> (A)	349
[Reproduction of experimental leprosy infection in mice with previously induced insufficiency of mononuclear phagocyte system.] Vishnevetsky, F. E., <i>et al.</i> (A)	910
Resistance of <i>M. avium</i> to microbicidal activities in bone-marrow macrophages from naturally susceptible (C57BL/6) and naturally resistant (DBA-2) mice. Rastogi, N. and Frehel, C. (A)	920

Response of the murine hematopoietic system to chronic infection with <i>M. lepraemurium</i> . Resnick, M., <i>et al.</i> (A)	593
Serum lactate dehydrogenase in murine leprosy: source and isozymes. Luna Herrera, J. and Rojas-Espinosa, O. (O)	641
The activity of minocycline against <i>M. leprae</i> -infected mice. Gelber, R., <i>et al.</i> (A)	317
Vaccination of mice against <i>M. leprae</i> infection. Singh, N. B., <i>et al.</i> (A)	717
Mice, nude,	
Attempts to select rifampicin-resistant <i>M. leprae</i> in nude mice. McDermott-Lancaster, R. D., <i>et al.</i> (A)	350
Effect of lyophilization on viability of <i>M. leprae</i> multiplied in nude mouse. Nakamura, M. and Kohsaka, K. (A)	908
<i>M. leprae</i> -susceptibility of NOD hybrid nude mice. Yogi, Y. and Nakamura, K. (A)	722
Macrophage mediated immune responses in the sciatic nerves of <i>M. leprae</i> infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., <i>et al.</i> (A)	310
Non-immune clearance of <i>M. leprae</i> from the footpads of <i>M. leprae</i> -infected, multidrug-treated nude mice. Chehl, S. K., <i>et al.</i> (A)	349
The nude mouse as an experimental lepromatous leprosy model (continued): the NFS/N nude mouse as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. (A)	721
Microscopy,	
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., <i>et al.</i> (A)	310
Reliability of direct skin smear microscopy in leprosy. Gupte, M. D., <i>et al.</i> (A)	570
Minocycline,	
The activity of minocycline against <i>M. leprae</i> -infected mice. Gelber, R., <i>et al.</i> (A)	317
Mitsuda reaction,	
Specific anti- <i>M. leprae</i> PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., <i>et al.</i> (O)	794
Monkey(s),	
Intraocular pressure changes with posture in experimentally induced Hansen's disease of mangabey and African green monkeys. Hussein, N., <i>et al.</i> (A)	354
Leprosy in three species of monkeys—an overview. Walsh, G. P., <i>et al.</i> (A)	310
Ontogenesis of antibodies in rhesus monkeys infected with <i>M. leprae</i> . Mukherjee, R., <i>et al.</i> (A)	309
Serologic responses to <i>M. leprae</i> -specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., <i>et al.</i> (A)	309
Monocyte(s),	
Differences in uptake of mycobacteria by human monocytes; a role for complement. Swartz, R. P., <i>et al.</i> (A)	595
Killing of human monocytes by specific cytotoxic T cells and nonspecific, MHC unrestricted killer cells after activation by mycobacterial antigens. Kaleab, B., <i>et al.</i> (A)	311
Suppression of monocyte oxidative response by phenolic glycolipid I of <i>M. leprae</i> . Vachula, M., <i>et al.</i> (A)	718
Morocco,	
Bilan de sept années d'enquêtes systématiques de la lèpre au Maroc. Sekkat, A., <i>et al.</i> (A)	324
Morphology,	
An electron microscopic study of alterations in the morphology and permeability of purified <i>M. leprae</i> . Prabhakaran, K., <i>et al.</i> (A)	720
Hepatic morphology in reactional states of leprosy. Patnaik, J. K., <i>et al.</i> (O)	499
Morphology of <i>M. leprae</i> (?) in VS3E medium—a preliminary communication. Bhatia, V. N. and Rao, S. (A)	906
Morphological index (MI),	
Effect of chemotherapy on viability of <i>M. leprae</i> as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., <i>et al.</i> (O)	615

Multidrug therapy (MDT),

- A bacteriological assessment of multibacillary cases in leprosy colonies after 4½ years of multidrug therapy. Naik, S. S., *et al.* (A) 129
- A new concept of staging paucibacillary leprosy and its application to the analysis of post-treatment results of a MDT study in Malawi. Boerrigter, G. and Ponnighaus, J. M. (A) 306
- Changes in epidemiological indices following introduction of WHO MDT into domiciliary HD programme. Rose, P. (A) 333
- Computerized management information system (COMIS) for monitoring MDT programme for leprosy. Revankar, C. R., *et al.* (A) 331
- Effect of multidrug therapy on the levels of antibodies to *M. leprae* glycolipid-I in the leprosy spectrum. Vaishnavi, C., *et al.* (A) 580
- [Effects of MDT on multibacillary leprosy for three years.] Li, W., *et al.* (A) 567
- Epidemiological impact of multidrug therapy in Gudiyatham control area, Karigiri. Rao, P. S. S., *et al.* (A) 331
- [Factors influencing the compliance of patients in MDT therapy in Anhui Province.] Xu, R., *et al.* (A) 131
- Five years of experience with MDT in the ALERT leprosy control programme. Desta, Z. and Becx-Bleumink, M. (A) 335
- Follow up of T cell subsets and anti-trisaccharide IgM antibody levels of leprosy patients during daily multidrug therapy. Desforges, S., *et al.* (A) 899
- Gradual setting up of multidrug therapy (WHO-MDT) in Brazil. Oliveira, M. L. W., *et al.* (A) 333
- [Guinea: detection of leprosy and multidrug therapy.] Bourée, P., *et al.* (A) 565
- Impact of MDT on incidence rates of leprosy among household contacts. Part 1. Baseline data. Sundar Rao, P. S. S., *et al.* (O) 647
- Impact of MDT on leprosy as measured by selective indicators. Jesudasan, K., *et al.* .. (A) 145
- Impact of multidrug therapy on leprosy in Baroda District (Gujarat). Chopra, N. K., *et al.* (A) 892
- Lactate dehydrogenase isoenzymes in leprosy patients on multidrug therapy—a preliminary report. Dhandayuthapani, S. and Bhatia, V. N. (A) 132
- Lepra reactions and disabilities in patients treated with daily MDT in New Caledonia, French Polynesia and Guadeloupe. Bobin, P., *et al.* (A) 313
- Leprosy control in the state of Amazonas, based on MDT (WHO/82). Talhari, S., *et al.* (A) 334
- Leprosy control through multidrug therapy using primary health care approach. Lopez-Bravo, L. and Noordeen, S. K. (A) 330
- Multidrug therapy—an effective tool in leprosy control programme. Rao, B. R. (A) 331
- Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday* by the World Health Organization. (B) 122
- Multidrug therapy for treatment of paucibacillary leprosy: the western Kenya experience. Orege, P. A., *et al.* (A) 341
- Multidrug therapy in paucibacillary leprosy—a five year experience. Grugni, A., *et al.* (A) 567
- Multiterapia de la lepra. Terencio de las Aguas, J. and Gomez Echevarria, J. R. (A) 324
- Operational aspects of multidrug therapy. Becx-Bleumink, M. (E) 540
- Patterns of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982). Reddy, P. K. and Mohinuddin, S. K. (A) 568
- Paucibacillary leprosy: a comparative study of different schedules of multidrug therapy. Ramakrishnan, K. R., *et al.* (A) 567
- Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988.* (B) 124
- Reactions in leprosy: a study of 250 patients in MDT project, Baroda District (Gujarat). Chopra, M. K., *et al.* (A) 313
- Relapse of paucibacillary leprosy after short course multidrug therapy. Pavithran, K. .. (A) 130
- Relapses after multidrug therapy for leprosy: a preliminary report on 22 cases in West Nepal. van Brakel, W., *et al.* (A) 894
- Results after 5 years of multidrug therapy (MDT) according to WHO recommendations for leprosy patients in Curupaiti (Brazil). Andrade, V. L. G., *et al.* (A) 335

Results after 8 years of a daily multidrug therapy for leprosy patients in Guadeloupe, New Caledonia and Polynesia. Cartel, J. L., <i>et al.</i> (A)	335
Selection of MDT strategies through epidemiometric modeling. Lechat, M. F., <i>et al.</i> . . (A)	323
Short-term multidrug therapy in multibacillary leprosy—review of 80 cases in two provinces of China (1983–1988). Li, H.-Y., <i>et al.</i> (O)	622
Surveillance and relapse rates after MDT in over 700 paucibacillary leprosy cases—a two years follow up at Purulia, India. Casablanca, M. N. and Nayagam, A. S. (A)	339
Technical problems related to multidrug therapy in leprosy control. Sansarricq, H. . . . (A)	324
The eye in multidrug therapy. Rajan, M. A. (A)	355
The global leprosy situation and the implementation of leprosy control through multidrug therapy. Noordeen, S. K. and Lopez-Bravo, L. (A)	324
[Treatment of multibacillary leprosy with MDT for one year.] Cui, C., <i>et al.</i> (A)	128
WHO MDT regime in Molucas Province (East Indonesia), January 1982–December 1987. Louhenapessy, A. and Sugiene, R. (A)	336
WHO multidrug therapy—a review of 956 domiciliary patients starting MDT between December 1981 and December 1987. Benjamin-Huntley, R. and Rose, P. (A)	335
Mycobacteria (see also individual species),	
Analysis of mycobacterial ribosomal RNA. Estrada-G., I., <i>et al.</i> (A)	327
Comparative intracellular growth of difficult-to-grow and other mycobacteria in a macrophage cell line. Rastogi, N., <i>et al.</i> (A)	920
Comparative studies of antigenic glycolipids of mycobacteria related to the leprosy bacillus. Minnikin, D. E., <i>et al.</i> (A)	908
Comparison of sensitivity of <i>Mycobacterium</i> spp. to combinations of clavulanic acid & penicillins with certain antitubercular agents. Bhattacharya, C. P., <i>et al.</i> (A)	589
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., <i>et al.</i> (A)	914
[Determination of antibodies to mycobacterial antigens in tuberculosis by the method of erythroimmunoabsorption with a rosette marker.] Plaksin, D. Y., <i>et al.</i> (A)	140
Development of genetic systems for the mycobacteria. Jacobs, W. R., Jr., <i>et al.</i> (A)	907
Differences in uptake of mycobacteria by human monocytes; a role for complement. Swartz, R. P., <i>et al.</i> (A)	595
Do environmental mycobacteria influence the distribution of disease in the leprosy spectrum? Bacteriological and skin test studies carried out in Iran. Velayati, A., <i>et al.</i> (A)	320
Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., <i>et al.</i> (A)	590
Effects of freezing-thawing of <i>M. leprae</i> and cultivable mycobacteria. Portaels, F., <i>et al.</i> (A)	329
Further evidence for an extended capsule of pathogenic mycobacteria. Draper, P. (A)	321
Identification of mycobacterial antigens recognized by T lymphocytes. Lamb, J. R., <i>et al.</i> (A)	714
<i>In vitro</i> activity of seventeen antimicrobial compounds against seven species of mycobacteria. Collins, C. G. and Uttley, A. H. C. (A)	728
Insertion elements in mycobacteria. Green, E. P., <i>et al.</i> (A)	916
Investigation of the effect of heat enhancement on the growth of mycobacteria in radiometric medium. Cutler, S. J. (A)	589
Isoenzyme profiles in slowly growing and difficult-to-grow mycobacteria. Blom-Potar, M.-C., <i>et al.</i> (A)	912
LDH isoenzyme as a tool for the identification of mycobacteria. Dhandayuthanpani, S., <i>et al.</i> (A)	728
Non-cultivable mycobacteria in ulcers of the skin. Salem, J. I., <i>et al.</i> (A)	920
Pyrimidine biosynthesis in <i>M. leprae</i> and other intracellular mycobacteria. Wheeler, P. R. (A)	909
Rapid and precise diagnosis of atypical mycobacterial infection by chemotaxonomical and immunological methods. Ikawa, H., <i>et al.</i> (A)	916
Reduction of tellurite and deesterification of fluorescein diacetate are not well correlated with the viability of mycobacteria. Mor, N., <i>et al.</i> (A)	142
Sensitisation by mycobacteria and the effects of BCG on children attending schools in the slums of Bombay. Stanford, J. L., <i>et al.</i> (A)	595

Serology of mycobacteria: characterization of antigens recognized by monoclonal antibodies. Young, D. B. and Mehlert, A. (A)	719
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Cree, I. A., <i>et al.</i> (A)	576
Size and homology of the genomes of leprosy-derived corynebacteria, <i>M. leprae</i> , and other corynebacteria and mycobacteria. Antoine, I., <i>et al.</i> (A)	142
Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., <i>et al.</i> (A)	582
Structure and function of mycobacterial glycolipids and glycopeptidolipids. Chatterjee, D., <i>et al.</i> (A)	906
Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Brennan, P. J. (A)	712
Studies on lipids in mycobacterial cell wall: their important structure and function relating to pathogenicity and their biological activity. Bera, A. and Banerjee, A. (A)	905
Studies on ribosomal RNA genes of mycobacteria including <i>M. leprae</i> . Katoch, V. M., <i>et al.</i> (A)	907
The 65 kilodalton antigen of mycobacteria. Shinnick, T. (A)	329
The influence of associated mycobacteria on the growth and pathogenicity of <i>M. leprae</i> . Kazda, J. (A)	322
Use of a cutoff range in identifying mycobacteria by the Gen-Probe rapid diagnostic system. Sherman, I., <i>et al.</i> (A)	594
Use of monoclonal antibodies in the identification of mycobacterial antigens. Kolk, A. H. J., <i>et al.</i> (A)	322

***Mycobacterium avium*, *M. avium* complex,**

Ability of smooth and rough variants of <i>M. avium</i> and <i>M. intracellulare</i> to multiply and survive intracellularly: role of C-mycosides. Rastogi, N., <i>et al.</i> (A)	730
Amikacin, ciprofloxacin, and imipenem treatment for disseminated <i>M. avium</i> complex infection of beige mice. Inderlied, C. B., <i>et al.</i> (A)	591
Antimicrobial synergism against <i>M. avium</i> complex strains isolated from patients with acquired immune deficiency syndrome. Yajko, D. M., <i>et al.</i> (A)	596
Bacterial antigen processing in macrophages infected with the obligate intracellular bacterium, <i>M. avium</i> . de Chastellier, C. and Lang, T. (A)	914
Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for <i>M. avium</i> complex. Lindholm-Levy, P. J. and Heifets, L. B. (A)	149
Comparative <i>in vitro</i> and <i>in vivo</i> activity of rifabutin and rifampicin against <i>M. avium</i> complex. Saito, H., <i>et al.</i> (A)	150
Concentration of <i>M. avium</i> by hospital hot water systems. du Moulin, G. C., <i>et al.</i> (A)	590
Correlations among naturally occurring resistances to antituberculosis drugs in <i>M. avium</i> complex strains. Tsukamura, M. and Miyachi, T. (A)	920
Evidence that host-recycling of <i>M. avium</i> preserves its ability to hinder macrophage killing functions. Frehel, C., <i>et al.</i> (A)	915
Genetic relatedness among <i>M. paratuberculosis</i> and <i>M. avium</i> complex. Labidi, A. and Thoen, C. O. (A)	917
Host defense against <i>M. avium</i> complex. Schnittman, S., <i>et al.</i> (A)	594
Human gut wall reactivity to monoclonal antibodies against <i>M. avium</i> glycolipid in relation to Crohn's disease (preliminary results). Blaauwgeers, J. L. G., <i>et al.</i> (A)	912
Identification and partial characterization of <i>M. avium</i> and <i>M. intracellulare</i> by using DNA probes. Saito, H., <i>et al.</i> (A)	731
Improved detection of <i>M. avium</i> complex with the BACTEC radiometric system. Hoffner, S. E. (A)	590
<i>M. avium-intracellulare</i> infection associated with hairy-cell leukemia. Maurice, P. D. L., <i>et al.</i> (A)	149
Methionine as methyl-group donor in the synthesis of <i>M. avium</i> envelope lipids, and its inhibition by DL-ethionine, D-norleucine and DL-norleucine. David, H. L., <i>et al.</i> (A)	914
Phagosome-lysosome fusions in macrophages infected with <i>M. avium</i> : role of mycosides-C and other cell surface components. Frehel, C. and Rastogi, N. (A)	915

Resistance of <i>M. avium</i> to microbicidal activities in bone-marrow macrophages from naturally susceptible (C57BL/6) and naturally resistant (DBA-2) mice. Rastogi, N. and Frehel, C. (A)	920
Serologic and immunocytochemical analysis of the <i>M. avium</i> cell envelope. David, H. L., et al. (A)	914
Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on <i>M. avium</i> complex. Hoffner, S. E., et al. (A)	916
Susceptibilities of <i>M. leprae</i> and <i>M. avium</i> complex to the H ₂ O ₂ -Fe-mediated halogenation system supplemented with antimicrobial agents. Tomioka, H., et al. (O)	628
The hamster model of chronic <i>M. avium</i> complex infection. Yangco, B. G., et al. (A)	732
The use of DNA probes identifying restriction-fragment-length polymorphisms to examine the <i>M. avium</i> complex. McFadden, J. J., et al. (A)	149
<i>Mycobacterium bovis</i>,	
Genetic relatedness among <i>M. tuberculosis</i> and <i>M. bovis</i> . Labidi, A. and Thoen, C. O. (A)	917
Homology of the 70-kilodalton antigens from <i>M. leprae</i> and <i>M. bovis</i> with the <i>M. tuberculosis</i> 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., et al. (A)	583
<i>In-vitro</i> susceptibility of <i>M. tuberculosis</i> , <i>M. bovis</i> and <i>M. kansasii</i> to amoxycillin and ticarcillin in combination with clavulanic acid. Wong, C. S., et al. (A)	732
Use of recombinant antigens expressed in <i>Escherichia coli</i> K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of <i>M. bovis</i> BCG. Thole, J. E. R., et al. (A)	717
<i>Mycobacterium fortuitum</i>,	
Beta-lactamase production and biological characteristics in nitrosoguanidine induced <i>M. fortuitum</i> mutants. Fattorini, L., et al. (A)	914
Isoenzymes as tools to discriminate various subdivisions in the <i>M. fortuitum</i> complex. Blom-Potar, M.-C., et al. (A)	913
Structure of pAL5000, a plasmid from <i>M. fortuitum</i> and its utilization in transformation of mycobacteria. Gicquel-Sanzey, B., et al. (A)	906
<i>Mycobacterium habana</i>,	
Use of nonconventional antigen, <i>M. habana</i> , in detecting <i>M. leprae</i> antibodies from leprosy patients and contacts in FLA-ABS test. Rana, N. S., et al. (A)	580
<i>Mycobacterium intracellulare</i>,	
Ability of smooth and rough variants of <i>M. avium</i> and <i>M. intracellulare</i> to multiply and survive intracellularly: role of C-mycosides. Rastogi, N., et al. (A)	730
Identification and partial characterization of <i>M. avium</i> and <i>M. intracellulare</i> by using DNA probes. Saito, H., et al. (A)	731
<i>Mycobacterium leprae</i>,	
A 28-kDa protein from <i>M. leprae</i> is a target of the human antibody response in lepromatous leprosy. Cherayil, B. J. and Young, R. A. (A)	575
A component of <i>M. leprae</i> as a serodiagnostic tool for leprosy. Ranade, A. and Mahadevan, P. R. (A)	903
A critique on the interpretation of the lepromin reaction using heat-killed <i>M. leprae</i> vaccine. Mistry, N. F. and Antia, N. H. (C)	110
A <i>M. leprae</i> -specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Anderson, D. C., et al. (A)	136
A peptidoglycan protein complex purified from <i>M. leprae</i> cell walls contains most or all immunodominant <i>M. leprae</i> T-cell antigens. Mutis, T., et al. (O)	788
A protein antigen of <i>M. leprae</i> is related to a family of small heat shock proteins. Nerland, A. H., et al. (A)	585
A species-specific repetitive sequence in <i>M. leprae</i> DNA. Clark-Curtiss, J. E. and Docherty, M. A. (A)	583
A study of the relatedness of <i>M. leprae</i> isolates using restriction fragment length polymorphism analysis. Williams, D. L. and Gillis, T. P. (A)	909
An electron microscopic study of alterations in the morphology and permeability of purified <i>M. leprae</i> . Prabhakaran, K., et al. (A)	720
Appraisal of two <i>M. leprae</i> -specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Sinha, S., et al. (O)	24

Attempts to select rifampicin-resistant <i>M. leprae</i> in nude mice. McDermott-Lancaster, R. D., <i>et al.</i> (A)	350
Benefits of recombinant DNA technology for the study of <i>M. leprae</i> . Clark-Curtiss, J. E. (A)	906
Characteristics of the multiplication of dapsone-resistant strains of <i>M. leprae</i> in mice. THELEP Clinical Trials Subcommittee (A)	131
Characterization and taxonomic implications of the rRNA genes of <i>M. leprae</i> . Sela, S., <i>et al.</i> (A)	585
Characterization of an antibody-binding epitope from the 18-kDa protein on <i>M. leprae</i> . Doherty, T. M., <i>et al.</i> (A)	719
Characterization of <i>M. leprae</i> cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., <i>et al.</i> (A)	715
Comparative biochemical analysis of the genomes of leprosy associated bacteria (<i>M. leprae</i> , LDC and ADM). Coene, M., <i>et al.</i> (A)	320
Construction of genomic library of <i>M. leprae</i> gene and its expression in <i>Streptomyces lividans</i> . Makino, M., <i>et al.</i> (A)	328
Cultivation of <i>M. leprae</i> : a new approach. Bapat, C. V. (C)	874
Detection of a specific <i>M. leprae</i> antigen in the urine of leprosy patients. Mahon, A. C., <i>et al.</i> (A)	326
[Determination of the viability of <i>M. leprae</i> with fluorescent staining.] Meng, M., <i>et al.</i> (A)	584
Double résistance RMP-dapsone dans 12 souches de <i>M. leprae</i> en Martinique: étude rétrospective, analyse des causes et prospective. Constant-Desportes, M., <i>et al.</i> (A)	335
Effect of chemotherapy on viability of <i>M. leprae</i> as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., <i>et al.</i> (O)	615
Effect of lyophilization on viability of <i>M. leprae</i> multiplied in nude mouse. Nakamura, M. and Kohsaka, K. (A)	908
Effect of <i>M. leprae</i> -infected Schwann cells and their supernatant on lymphocyte neuroglia interaction. Mehta, R., <i>et al.</i> (A)	902
[Effect of removal of the popliteal ganglion on multiplication of <i>M. leprae</i> in the mouse foot-pad: preliminary report.] Moreno, O. S. and Silveira, J. R. (A)	143
Effects of a derivative of serotonin (deoxyfructoserotonin) and other antileprosy drugs on attachment and uptake of <i>M. leprae</i> by Schwann cells <i>in vitro</i> . Chaudhury, A., <i>et al.</i> (A)	893
Effects of freezing-thawing of <i>M. leprae</i> and cultivable mycobacteria. Portaels, F., <i>et al.</i> (A)	329
Evidence for phagosome-lysosome fusion in <i>M. leprae</i> -infected murine Schwann cells. Steinhoff, U., <i>et al.</i> (A)	717
Expression in recombinant <i>E. coli</i> of biotinylated proteins of <i>M. leprae</i> . Moss, M. T. and Dale, J. W. (A)	327
Expression of the <i>M. leprae</i> 18 kD protein. Stoker, N. G., <i>et al.</i> (A)	329
Expression, purification and immunologic activity of recombinant 65-kilodalton protein of <i>M. leprae</i> . Gillis, T. P. and Williams, D. L. (A)	328
Filamentous phase in life cycle of <i>M. leprae</i> (?): a preliminary communication. Bhatia, V. N. (A)	142
Fluorescent staining procedure (FDA/EB) for determining the viability of <i>M. leprae</i> . Meng, M.-B., <i>et al.</i> (A)	322
Genetic relationships among <i>M. leprae</i> , <i>M. tuberculosis</i> , and candidate leprosy vaccine strains determined by DNA hybridization: identification of an <i>M. leprae</i> -specific repetitive sequence. Grosskinsky, C. M., <i>et al.</i> (A)	719
Genomic and amino acid sequence of the <i>M. leprae</i> 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., <i>et al.</i> (A)	318
Homology of the 70-kilodalton antigens from <i>M. leprae</i> and <i>M. bovis</i> with the <i>M. tuberculosis</i> 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., <i>et al.</i> (A)	583
Identification of <i>M. leprae</i> antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., <i>et al.</i> (O)	652
Immunogold labeling method for <i>M. leprae</i> -specific phenolic glycolipid in glutaraldehyde-osmium-fixed and araldite-embedded leprosy lesions. Boddington, J. and Dijkman, H. P. (A)	913

<i>In vitro</i> cultivation of <i>M. leprae</i> under microaerophilic conditions. Ishaque, M.	(A)	321
<i>In vitro</i> interaction of <i>M. leprae</i> -infected Schwann cells and splenic cells. Mehra, R., <i>et al.</i>	(A)	579
<i>In vitro</i> screening of antileprosy drugs by mass spectrometric analysis of <i>M. leprae</i> . Lindner, B., <i>et al.</i>	(A)	350
Intracellular parasitism of parenchymal cells by <i>M. leprae</i> . Job, C. K., <i>et al.</i>	(O)	659
Investigations into cultivation of <i>M. leprae</i> under low oxygen tension. Ishaque, M.	(C)	115
Isolation and characterization of the highly immunogenic cell wall-associated protein of <i>M. leprae</i> . Hunter, S. W., <i>et al.</i>	(A)	713
Limited <i>in vitro</i> multiplication of <i>M. leprae</i> . Dhople, A. M., <i>et al.</i>	(A)	320
<i>M. leprae</i> persists in patients treated with rifampicin and acedapsone. Gonzalez, A. B., <i>et al.</i>	(A)	335
Measurement of ATP content of <i>M. leprae</i> —its application to the determination of viability and drug sensitivity screening. Katoch, V. M., <i>et al.</i>	(A)	321
Metabolism in <i>M. leprae</i> , <i>M. tuberculosis</i> and other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C.	(A)	143
Molecular relatedness among <i>M. leprae</i> isolates defined using recombinant DNA probe. Clark-Curtiss, J. E.	(A)	327
Monitoring of <i>in vivo</i> response of <i>M. leprae</i> to antileprosy therapies. Haas, M., <i>et al.</i>	(A)	350
Morphology of <i>M. leprae</i> (?) in VS3E medium—a preliminary communication. Bhatia, V. N. and Rao, S.	(A)	906
New data on the ultrastructure of the membrane of <i>M. leprae</i> . Silva, M. T., <i>et al.</i>	(O)	54
Non-immune clearance of <i>M. leprae</i> from the footpads of <i>M. leprae</i> -infected, multidrug-treated nude mice. Chehl, S. K., <i>et al.</i>	(A)	349
Preliminary results on the detection of mycolic acids from <i>M. leprae</i> by gel permeation chromatography and proton nuclear resonance spectroscopy. Gan, S. C., <i>et al.</i>	(A)	583
Presence of mycobactin-like substance in <i>M. leprae</i> . Dhople, A. M. and Osborne, L. J.	(A)	142
Purification of <i>M. leprae</i> with special reference to the effects of purified <i>M. leprae</i> vaccines and host macrophage cell functions. Saito, H., <i>et al.</i>	(A)	904
Pyrimidine biosynthesis <i>de novo</i> in <i>M. leprae</i> . Wheeler, P. R.	(A)	720
Pyrimidine biosynthesis in <i>M. leprae</i> and other intracellular mycobacteria. Wheeler, P. R.	(A)	909
Pyrimidine scavenging by <i>M. leprae</i> . Wheeler, P. R.	(A)	720
Recognition of <i>M. leprae</i> Antigens. Ottenhoff, T. and de Vries, R. R. P.	(A)	139
Relapse in LL patients after antileprosy ICRC vaccine: its significance to antigenic variability of <i>M. leprae</i> . Bapat, C. V.	(A)	349
Selective coating of <i>M. leprae</i> surface antigens by species and genus-specific mycobacterial antibodies and its effect on phagosome-lysosome fusions in <i>M. leprae</i> -infected macrophages. Rastogi, N. and Frehel, C.	(A)	326
Size and homology of the genomes of leprosy-derived corynebacteria, <i>M. leprae</i> , and other corynebacteria and mycobacteria. Antoine, I., <i>et al.</i>	(A)	142
Structure-activity relationships of selected phenazines against <i>M. leprae in vitro</i> . Franzblau, S. G. and O'Sullivan, J. F.	(A)	566
Studies on energy synthesis in <i>M. leprae</i> . Bharadwaj, V. P., <i>et al.</i>	(A)	906
Studies on ribosomal RNA genes of mycobacteria including <i>M. leprae</i> . Katoch, V. M., <i>et al.</i>	(A)	907
Susceptibilities of <i>M. leprae</i> and <i>M. avium</i> complex to the H ₂ O ₂ -Fe-mediated halogenation system supplemented with antimicrobial agents. Tomioka, H., <i>et al.</i>	(O)	628
T cell epitopes on the 36K and 65K <i>M. leprae</i> antigens defined by human T cell clones. van Schooten, W. C. A., <i>et al.</i>	(A)	141
T cell responses to fractionated <i>M. leprae</i> antigens in leprosy. The lepromatous non-responder defect can be overcome <i>in vitro</i> by stimulation with high molecular weight <i>M. leprae</i> components. Ottenhoff, T., <i>et al.</i>	(A)	326
The influence of associated mycobacteria on the growth and pathogenicity of <i>M. leprae</i> . Kazda, J.	(A)	322
The large molecular mass cell wall protein of <i>M. leprae</i> . Hunter, S. W., <i>et al.</i>	(A)	320
The primary structure of the 16SrRNA of <i>M. leprae</i> : its use in phylogeny and development of DNA probes. Stackebrandt, E., <i>et al.</i>	(A)	908

- The role of the 65-kDa protein in the immune response to *M. leprae*. Colston, M. J., *et al.* (A) 325
- The use of a "universal" yeast expression vector to produce an antigenic protein of *M. leprae*. Booth, R. J., *et al.* (A) 575
- Use of DNA probes to investigate the genetics of *M. leprae*. McFadden, J., *et al.* (A) 328
- Viability of *M. leprae* in soil and dead armadillo tissue and its significance. Harris, E. B., *et al.* (A) 323
- Mycobacterium lepraemurium*,**
- A histopathological study of pulmonary infection of mice with *M. lepraemurium*. Ha, D. K. K., *et al.* (A) 590
- [Development of experimental infection with *M. lepraemurium* in two strains of mice.] Roggero, E., *et al.* (A) 731
- Macrophage activity in resistant and susceptible mouse strains infected with *M. lepraemurium*. Brett, S. J. and Butler, R. (A) 589
- The role of CD8+ cells in resistance and delayed hypersensitivity reactions in *M. lepraemurium* infection. Curtis, J., *et al.* (A) 308
- Mycobacterium marinum*,**
- Specificity and antigenicity of mycoside G and other glycolipids from *M. marinum*. Cruaud, P., *et al.* (A) 913
- Studies on adenylate kinase (ATP:AMP phosphotransferase) of *M. marinum* (ATCC 927). Batra, P. P., *et al.* (A) 912
- Mycobacterium microti*,**
- Biosynthesis of phenolic glycolipids in *M. microti*. Thurman, P. and Draper, P. (A) 920
- Mycobacterium paratuberculosis*,**
- Genetic relatedness among *M. paratuberculosis* and *M. avium* complex. Labidi, A. and Thoen, C. O. (A) 917
- Mycobacterium smegmatis*,**
- [Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* (A) 718
- Expression of heterologous genes by lysates of *M. smegmatis*. Lamb, F. I., *et al.* (A) 328
- Human disease due to *M. smegmatis*. Wallace, R. J., Jr., *et al.* (A) 596
- Transformation of *M. smegmatis* with *Escherichia coli* plasmids carrying a selectable resistance marker. Zainuddin, Z. F., *et al.* (A) 720
- Mycobacterium tuberculosis*,**
- A cloned DNA fragment for identification of *M. tuberculosis*. Patel, R. J., *et al.* (A) 730
- Activation of $\gamma\delta$ T cells in the primary immune response to *M. tuberculosis*. Janis, E. M., *et al.* (A) 900
- Association of tuberculosis and *M. tuberculosis*-specific antibody levels with HLA. Bothamley, G. H., *et al.* (A) 727
- Direct antimicrobial drug susceptibility testing of *M. tuberculosis* by the radiometric method. Libonati, J. P., *et al.* (A) 592
- Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* (A) 917
- Genetic relatedness among *M. tuberculosis* and *M. bovis*. Labidi, A. and Thoen, C. O. (A) 917
- Genetic relationships among *M. leprae*, *M. tuberculosis*, and candidate leprosy vaccine strains determined by DNA hybridization: identification of an *M. leprae*-specific repetitive sequence. Grosskinsky, C. M., *et al.* (A) 719
- Homology of the 70-kilodalton antigens from *M. leprae* and *M. bovis* with the *M. tuberculosis* 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., *et al.* (A) 583
- In vitro* activity of ciprofloxacin in combination with standard antituberculous drugs against *M. tuberculosis*. Uttley, A. H. C. and Collins, C. H. (A) 151
- In-vitro* susceptibility of *M. tuberculosis*, *M. bovis* and *M. kansasii* to amoxycillin and ticarcillin in combination with clavulanic acid. Wong, C. S., *et al.* (A) 732

Intraspecies differentiation of strains of <i>M. tuberculosis</i> obtained from Czechoslovakian, Mongolian and South Indian patients. Venkataraman, P., <i>et al.</i> (A)	596
Metabolism in <i>M. leprae</i> , <i>M. tuberculosis</i> and other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. (A)	143
Monoclonal antibodies to 33 kD protein of <i>M. tuberculosis</i> with varying epitope specificities. Rambukkana, A., <i>et al.</i> (A)	903
Preliminary evaluation of a <i>M. tuberculosis</i> phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., <i>et al.</i> (A)	151
Serodiagnostic potentialities of enzyme-linked immunosorbent assay (ELISA) using mannophosphoinositides of <i>M. tuberculosis</i> H37Rv. Mehta, P. K. and Khuller, G. K. (A)	729
Serological responses of patients with lepromatous and tuberculoid leprosy to 30-, 31-, and 32-kilodalton antigens of <i>M. tuberculosis</i> . Rumschlag, H. S., <i>et al.</i> (A)	140
Serological specificity of <i>M. tuberculosis</i> glycolipids. Papa, F., <i>et al.</i> (A)	918
<i>Mycobacterium ulcerans</i>,	
Immunosuppressive properties of the soluble toxin from <i>M. ulcerans</i> . Pimsler, M., <i>et al.</i> (A)	919
<i>Mycobacterium vaccae</i>,	
Inyecciones de <i>M. vaccae</i> muertas inducen respuestas intradermicas frente antigenos solubles del <i>M. leprae</i> en 50% de pacientes lepromatosos. Torres, P., <i>et al.</i> (A)	320
<i>Mycobacterium w</i>,	
Results of one year of phase II/phase III trials with the candidate antileprosy vaccine <i>Mycobacterium w</i> . Zaheer, S. A., <i>et al.</i> (A)	351
<i>Mycobacterium xenopi</i>,	
Capillary gas chromatographic analysis of mycolic acid cleavage products, cellular fatty acids, and alcohols of <i>M. xenopi</i> . Luquin, M., <i>et al.</i> (A)	917
Mycobactin,	
Presence of mycobactin-like substance in <i>M. leprae</i> . Dhople, A. M. and Osborne, L. J. (A)	142
Nepal,	
Relapses after multidrug therapy for leprosy: a preliminary report on 22 cases in West Nepal. van Brakel, W., <i>et al.</i> (A)	894
Nerve(s),	
An enzyme immunoassay (EIA) based on antibodies against human nerve antigen for diagnosis of all categories of leprosy patients. Itty, B. M., <i>et al.</i> (A)	304
An experimental model of chronic nerve compression and the effect of <i>M. leprae</i> infection on a nerve with chronic compression neuropathy. Doyle, D., <i>et al.</i> (A)	309
Calcification of ulnar nerve in a patient with tuberculoid leprosy—a case report. Sidappa, K., <i>et al.</i> (A)	711
Calcification of ulnar nerve in leprosy—a case report. Arora, S. K., <i>et al.</i> (A)	709
Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. Karanth, S. S., <i>et al.</i> (A)	578
Chemical and mechanical neurolysis. Yanez Ordas, R. and Hernandez Angula, M. (A)	344
Comprehensive management of recent nerve damage in borderline leprosy on an out-patient basis. Udaya, K. K. and Suneetha, S. (A)	338
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. McDougall, A. C. (C)	114
Drs. Jacob and Mathai reply (diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy). Jacob, M. and Mathai, R. (C)	114
Gangliosides (Cronassial) and nerve regeneration in leprosy; a multicentre trial: preliminary results. Salafia, A., <i>et al.</i> (A)	317
Histology and fine structure of lepromatous nerves, before and after treatment. Dastur, D. K., <i>et al.</i> (A)	337
Immuno-electron microscopy of mycobacterial granulomas in the sciatic nerves of guinea pigs. Cowley, S. A., <i>et al.</i> (A)	310
Indications that early events causing nerve damage in leprosy may not be immunologically mediated. Antia, N. H., <i>et al.</i> (A)	337

Light- and electron-microscopic study of <i>M. leprae</i> -infected armadillo nerves. Liu, T.-C., <i>et al.</i>	(O)	65
Macrophage mediated immune responses in the sciatic nerves of <i>M. leprae</i> infected nude mice with possible bystander and autoimmune demyelination—an electron microscopic study. Stanley, J. N. A., <i>et al.</i>	(A)	310
Monitoring of patient peripheral nerve status and deformity in Hansen's disease. Bell-Krotoski, J.	(A)	337
Multibacillary lesions in nerves of patients with primary neuritic leprosy. Jacob, M. and Mathai, R.	(A)	338
Nerve damage in leprosy. Job, C. K.	(E)	532
<i>Nerves and Veins in Leprosy</i> by A. Mukherjee. Dharmendra	(B)	888
New boundaries for the indications for nerve decompressions. Theuvenet, W. J., <i>et al.</i>	(A)	344
Out patient treatment of nerve damage requiring corticosteroids in the ALERT leprosy control programme. Berhe, D. and Becx-Bleumink, M.	(A)	337
Preliminary results about a controlled double-blind study with three different kinds of treatment in severe nerve damage. Dietz, M. and Yemaneberhan, T.	(A)	338
Serum antibodies of normals and leprosy patients show equal binding to peripheral nerve. Ghaswala, P. S., <i>et al.</i>	(C)	690
Sural nerve biopsy findings in leprosy: a qualitative and quantitative light and electron microscopic study in 4 treated cases of the lepromatous spectrum. Gibbels, E., <i>et al.</i>	(A)	137
Surgical exploration of peripheral nerve enlargement. Dong, L.-W., <i>et al.</i>	(A)	342
The role of nerve biopsies in the diagnosis and management of leprosy. Nilsen, R., <i>et al.</i>	(A)	895
The significance of facial patches in relation to facial nerve damage in paucibacillary leprosy. Hogeweg, M., <i>et al.</i>	(A)	314
Traitement palliatif de la paralysie sciatique poplitée externe—étude critique—à propos de 30 cas. Oberlin, C.	(A)	343
Ultrastructural studies on peripheral nerves in lepromatous leprosy patients. Kumar, V., <i>et al.</i>	(A)	138
Netherlands, The,		
4th Immunodermatology Symposium.	(N)	558
XIII International Leprosy Congress.	(S)	229
Neuritis,		
Essai comparé randomisé de traitement des névrites hanséniennes par les corticoïdes seuls ou associés à une neurolyse. Boucher, P., <i>et al.</i>	(A)	342
[Five cases of recurring leprosy neuritis; surgical treatment.] Redondo, A., <i>et al.</i>	(A)	148
Neuritis—surgical decompression relieves intractable pain, tenderness and hyperaesthesia. Srinivasan, T., <i>et al.</i>	(A)	343
Surgical management of ulnar neuritis by hemicircumferential epineurotomy. Solomon, S. and Fritschi, E. P.	(A)	343
[Surgical treatment of leprosy neuritis; results of 114 operations.] Nores, J. M., <i>et al.</i>	(A)	588
[Tuberculoid leprosy with necrotizing neuritis and numerous bacilli in the fistulae.] de Menezes, J. A., <i>et al.</i>	(A)	569
Quelle orientation du traitement des névrites hanséniennes. Carayon, A., <i>et al.</i>	(A)	342
Neuropathy,		
An experimental model of chronic nerve compression and the effect of <i>M. leprae</i> infection on a nerve with chronic compression neuropathy. Doyle, D., <i>et al.</i>	(A)	309
The pathology of early leprosy neuropathy. Shetty, V. P., <i>et al.</i>	(A)	716
New Caledonia,		
Specific anti- <i>M. leprae</i> PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., <i>et al.</i>	(O)	794
Nigeria,		
An evaluation of 35 years of leprosy control in northern Nigeria as demonstrated in the original pilot project Katsina. Waaldijk, K.	(A)	324
Courses at a specialist leprosy hospital for the training of medical students and paramedical workers in Nigeria. Attah, E. B. and Davies, E. M.	(A)	347

The role of a geographer in leprosy research and control: case study from Nigeria. Brightmer, M. I.	(A)	322
Nose,		
Bacillaemia in leprosy: correlation with slit-skin and nasal smears. Chatterjee, G., <i>et al.</i>	(A)	569
Detection of lepromatous leprosy patients shedding <i>M. leprae</i> in nasal droppings by enzyme immunoassay. Moudgil, K. D., <i>et al.</i>	(A)	579
Epistaxis and leprosy. Soni, N. K.	(A)	573
Obituaries,		
Christian, Melville by Hastings, R. C.	(Ob)	697
Destá, Zerihun by Becx-Bleumink, M.	(Ob)	552
Gatti, Juan C. by Olivares, L. M.	(Ob)	698
Ma Haide by Ye, G.-Y.	(Ob)	117
Matthews, C. M. E. by Cherian, J.	(Ob)	883
Møller-Christensen, Vilhelm by Jopling, W. H.	(Ob)	553
Ofloxacin,		
Effect of ofloxacin on experimental leprosy. Kohsaka, K., <i>et al.</i>	(A)	316
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., <i>et al.</i>	(A)	325
Pefloxacin and ofloxacin activities against <i>M. leprae</i> in the mouse. Guelpa-Lauras, C.-C., <i>et al.</i>	(A)	316
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., <i>et al.</i>	(A)	317
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): II. Biological results. Grosset, J., <i>et al.</i>	(A)	316
Papua New Guinea,		
The epidemiology of leprosy in a high prevalence village in Papua New Guinea. Bag- shawe, A., <i>et al.</i>	(A)	722
Pathology,		
The pathology of early leprous neuropathy. Shetty, V. P., <i>et al.</i>	(A)	716
Pefloxacin,		
Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, peflox- acin, reference fluoroquinolones, and a new macrolide, clarithromycin. Gorzynski, E. A., <i>et al.</i>	(A)	915
Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., <i>et al.</i>	(A)	325
Pefloxacin and ofloxacin activities against <i>M. leprae</i> in the mouse. Guelpa-Lauras, C.-C., <i>et al.</i>	(A)	316
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): I. Clinical results. N'Deli, L., <i>et al.</i>	(A)	317
Pefloxacin or ofloxacin in lepromatous leprosy at Adzope (Ivory Coast): II. Biological results. Grosset, J., <i>et al.</i>	(A)	316
Phagocyte(s),		
Measurement of phagocyte chemiluminescence using a microtitre plate luminometer. Blair, A. L., <i>et al.</i>	(A)	575
Reactive oxygen intermediates inactivate <i>M. leprae</i> in the phagocytes from human peripheral blood. Marolia, J. and Mahadevan, P. R.	(O)	483
[Reproduction of experimental leprosy infection in mice with previously induced in- sufficiency of mononuclear phagocyte system.] Vishnevetsky, F. E., <i>et al.</i>	(A)	910
T lymphocytes, mononuclear phagocytes, Schwann cells and <i>M. leprae</i> . Kaufmann, S. H. E., <i>et al.</i>	(A)	900
Pharmacokinetics,		
Clinical pharmacokinetics of clofazimine; a review. Holdiness, M. R.	(A)	893
Structure pharmacokinetic relationship in a series of dapsone derivatives. Visser, K., <i>et</i> <i>al.</i>	(A)	317

Phenolic glycolipid(s),

- A preliminary study on serological activity of phenolic glycolipid and its application in diagnosis of leprosy. Wu, Q., *et al.* (A) 581
- Arabinogalactan; a complementary antigen to phenolic glycolipid in leprosy diagnosis. Roy, A., *et al.* (A) 580
- Biosynthesis of phenolic glycolipids in *M. microti*. Thurman, P. and Draper, P. (A) 920
- Comparative studies of serum IgA1, IgA2 and IgM against phenolic glycolipid I in leprosy patients and contacts. Chujor, C. S. N., *et al.* (A) 304
- Demonstration of PGL I antigens in skin biopsies in indeterminate leprosy patients: comparison with serological anti-PGL I levels. Huerre, M., *et al.* (A) 899
- Detection of phenolic glycolipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* (A) 897
- Detection of phenolic glycolipid I of *M. leprae* for monitoring the chemotherapy of leprosy. Cho, S.-N., *et al.* (A) 303
- Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* (A) 917
- Evaluation of natural phenolic glycolipid (GP1) and artificial antigen in the serodiagnosis of leprosy. Wu, Q.-Z., *et al.* (A) 305
- Frequency and polyreactivity of human antibodies to phen GL-I from leprosy patients defined by anti-idiotypes. Zumla, A., *et al.* (A) 304
- Human gut wall reactivity to monoclonal antibodies against *M. avium* glycolipid in relation to Crohn's disease (preliminary results). Blaauwgeers, J. L. G., *et al.* (A) 912
- Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., *et al.* (A) 582
- Immunogold labeling method for *M. leprae*-specific phenolic glycolipid in glutaraldehyde-osmium-fixed and araldite-embedded leprosy lesions. Boddington, J. and Dijkman, H. P. (A) 913
- Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., *et al.* (A) 905
- Long-term correlation between serological (PGL) and histological parameters in the control of chemotherapy in LL and BL patients. Wabitsch, K. R., *et al.* (A) 346
- Monitoring of PGLI antigen and antibody levels in multibacillary leprosy patients treated with ofloxacin or pefloxacin. Chanteau, S., *et al.* (A) 325
- PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., *et al.* (A) 897
- PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Chanteau, S., *et al.* (O) 735
- PGL-I independence of the lepromin (Mitsuda) reaction in pre-sensitized guinea pigs. Krotoski, W. A., *et al.* (A) 309
- Preliminary evaluation of a *M. tuberculosis* phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., *et al.* (A) 151
- Relationships between structure and biological activity of the mycolic acid-containing glycolipids from *Nocardia asteroides* "sensu stricto" and related species. Han, Y., *et al.* (A) 916
- Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* (A) 309
- Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Burgess, P. J., *et al.* (A) 144
- Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* (O) 794
- Synthesis and immunoreactivity of neoglycoproteins containing the trisaccharide unit of phenolic glycolipid I of *M. leprae*. Chatterjee, D., *et al.* (A) 712
- The effect of phenolic glycolipid-I from *M. leprae* on the antimicrobial activity of human macrophages. Neill, M. A. and Klebanoff, S. J. (A) 139

Philippines, The,

- Evaluation of *M. leprae* antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines. Douglas, J. T., *et al.* (A) 899

Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., <i>et al.</i> (A)	339
Polynesia,	
Leprosy reactions and disabilities in patients treated with daily MDT in New Caledonia, French Polynesia and Guadeloupe. Bobin, P., <i>et al.</i> (A)	313
[Leprosy in French Polynesian archipelagoes from 1967–1987.] Cartel, J.-L., <i>et al.</i> (A)	722
PGL I antigen and antibody detection in the control of leprosy in French Polynesia. Chanteau, S., <i>et al.</i> (A)	897
Results after 8 years of a daily multidrug therapy for leprosy patients in Guadeloupe, New Caledonia and Polynesia. Cartel, J. L., <i>et al.</i> (A)	335
Pregnancy,	
[Hanseniasis and pregnancy; an evaluation of sulfone therapy.] dos Santos, I. B., <i>et al.</i> (A)	707
Prostaglandin,	
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. (A)	132
Prostaglandins and leprosy. A role for aspirin? Klenerman, P. (A)	901
Protein(s),	
A 28-kDa protein from <i>M. leprae</i> is a target of the human antibody response in lepromatous leprosy. Cherayil, B. J. and Young, R. A. (A)	575
A peptidoglycan protein complex purified from <i>M. leprae</i> cell walls contains most or all immunodominant <i>M. leprae</i> T-cell antigens. Mutis, T., <i>et al.</i> (O)	788
A protein antigen of <i>M. leprae</i> is related to a family of small heat shock proteins. Nerland, A. H., <i>et al.</i> (A)	585
Characterization of an antibody-binding epitope from the 18-kDa protein on <i>M. leprae</i> . Doherty, T. M., <i>et al.</i> (A)	719
Characterization of <i>M. leprae</i> cell wall-associated proteins with the use of T lymphocyte clones. Mehra, V., <i>et al.</i> (A)	715
Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., <i>et al.</i> (A)	590
Expression in recombinant <i>E. coli</i> of biotinylated proteins of <i>M. leprae</i> . Moss, M. T. and Dale, J. W. (A)	327
Expression of the <i>M. leprae</i> 18 kD protein. Stoker, N. G., <i>et al.</i> (A)	329
Expression, purification and immunologic activity of recombinant 65-kilodalton protein of <i>M. leprae</i> . Gillis, T. P. and Williams, D. L. (A)	328
Genomic and amino acid sequence of the <i>M. leprae</i> 70 kD antigen is homologous to the higher conserved 70 kD heat shock protein (hsp70) of eukaryotes. Garsia, R. J., <i>et al.</i> (A)	318
Homology of the 70-kilodalton antigens from <i>M. leprae</i> and <i>M. bovis</i> with the <i>M. tuberculosis</i> 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Garsia, R. J., <i>et al.</i> (A)	583
Isolation and characterization of the highly immunogenic cell wall-associated protein of <i>M. leprae</i> . Hunter, S. W., <i>et al.</i> (A)	713
Monoclonal antibodies to 33 kD protein of <i>M. tuberculosis</i> with varying epitope specificities. Rambukkana, A., <i>et al.</i> (A)	903
Overproduction and purification of <i>M. leprae</i> 65 kD protein in <i>Escherichia coli</i> . Nomaguchi, H., <i>et al.</i> (A)	329
Overproduction, affinity purification and characterization of 65-kDa protein of <i>M. leprae</i> in <i>Escherichia coli</i> . Nomaguchi, H., <i>et al.</i> (O)	817
Polyspecificity of human monoclonal antibodies reactive with <i>M. leprae</i> , mitochondria, ssDNA, cytoskeletal proteins, and the acetylcholine receptor. Duggan, D. B., <i>et al.</i> . . (A)	576
Stress proteins and the immune response to mycobacteria—antigens as virulence factors? Young, D. B., <i>et al.</i> (A)	582
Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Brennan, P. J. (A)	712
The large molecular mass cell wall protein of <i>M. leprae</i> . Hunter, S. W., <i>et al.</i> (A)	320

- The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* (A) 577
- The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* (A) 579
- The role of the 65-kDa protein in the immune response to *M. leprae*. Colston, M. J., *et al.* (A) 325
- The use of a "universal" yeast expression vector to produce an antigenic protein of *M. leprae*. Booth, R. J., *et al.* (A) 575
- Use of recombinant antigens expressed in *Escherichia coli* K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of *M. bovis* BCG. Thole, J. E. R., *et al.* (A) 717
- Psycho-social,**
- A study on risk factors in social displacement of leprosy patients. Thomas, M. V. (A) 353
- Bringing leprosy into the open. Chen, P. C. Y. (A) 127
- Care after cure in leprosy. Thomas, A. and Thomas, R. A. (A) 353
- Coping strategies for making the transition from isolation back into the community. Malo, W. and Malo, E. (A) 353
- Experience on trying to transform a "colony hospital" into "community institute." Amaral, R. R. and Barroso, M. S. (A) 351
- Experience with a multi-ethnic support group in the treatment of Hansen's disease. Gillen, J. and Gelber, R. (A) 352
- Governmental responsibilities in addressing the social stigma attached to individuals afflicted with Hansen's disease. Bellinger, R. (A) 346
- Hansen's disease: the stigma, the fear, the solution. Punikai'a, B. K. (A) 353
- Knowledge and attitude of leprosy workers: a case study in status analysis. Wele, D. S. (A) 348
- On being diagnosed a "leper." Olivier, H. R. (A) 565
- [Personality analysis of leprosy patients.] Zhou, D., *et al.* (A) 589
- Problems in the analysis of socio-economic risk factors in leprosy. Maine, N., *et al.* ... (A) 352
- Social science research on social dimensions of leprosy: where are we going from here? Valencia, L. B. (E) 847
- The leper's dilemma. Fleming, S. (A) 127
- The paradoxical stigma of leprosy. Meisels-Navon, L. (A) 348
- The stigma of leprosy. Gonzalez del Cerro, S. M. A. (A) 911
- Purified protein derivative (PPD),**
- Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* (A) 914
- Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* (A) 917
- The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* (A) 577
- Purines,**
- Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., *et al.* .. (A) 594
- Radioimmunoassay,**
- A monoclonal antibody based competition radioimmunoassay for monitoring anti-*M. leprae* antibodies in leprosy patients and contacts. Sinha, S., *et al.* (A) 573
- Rat(s),**
- Inefficacy of thalidomide on rat adjuvant-induced arthritis and lack of arthrogenicity of Hansen bacilli. Tsutsumi, S. and Gidoh, M. (A) 721
- Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., *et al.* (A) 131
- Reactions, leprosy,**
- Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction. Kar, H. K. and Roy, R. G. (A) 133

Reactions in leprosy: a study of 250 patients in MDT project, Baroda District (Gujarat). Chopra, N. K., <i>et al.</i> (A)	313
The management of reaction in leprosy. Pfaltzgraff, R. E. (E)	103
Vitiligo following type II lepra reaction. Pavithran, K. (A)	711

Rehabilitation,

Beyond charity: devising rehabilitation projects for a competitive economic world. Freitas, P. (A)	352
Motivating and training for reconstructive surgery and rehabilitation in a South American setting. Duerksen, F., <i>et al.</i> (A)	347
Posterior chamber intraocular lenses in the rehabilitation of leprosy patients. Alexander, T. A., <i>et al.</i> (A)	354
<i>Proceedings of the International Congress on Medical and Social Rehabilitation of the Disabled in the Third World Countries with Emphasis on the Rehabilitation of the Leprosy Patient.</i> (B)	563
Study on socio-economic rehabilitation. Gopal, P. K. (A)	352

Relapse(s),

[Calculation of relapse rate in leprosy and its significance.] Sun, X., <i>et al.</i> (A)	147
Patterns of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982). Reddy, P. K. and Mohinuddin, S. K. (A)	568
Rate and time distribution of relapses in multibacillary leprosy. Kurz, X. M., <i>et al.</i> . . . (O)	599
Relapse in LL patients after antileprosy ICRC vaccine: its significance to antigenic variability of <i>M. leprae</i> . Bapat, C. V. (A)	349
Relapse of paucibacillary leprosy after short course multidrug therapy. Pavithran, K. . . (A)	130
Relapse or late reversal reaction? Pannikar, V., <i>et al.</i> (E)	526
Relapse or reversal reaction: the case for a therapeutic trial of steroids. Ramachandran, A. and Seshadri, P. S. (A)	135
Relapse rate in paucibacillary patients during surveillance after multidrug treatment—preliminary report. Babu, G. R., <i>et al.</i> (A)	341
Relapse rates in paucibacillary leprosy—WHO regimen versus dapsone monotherapy. Jesudasan, K., <i>et al.</i> (A)	340
Relapses after multidrug therapy for leprosy: a preliminary report on 22 cases in West Nepal. van Brakel, W., <i>et al.</i> (A)	894
Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin. Katoch, K., <i>et al.</i> (O)	458
Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Grosset, J. H., <i>et al.</i> (O)	607
Surveillance and relapse rates after MDT in over 700 paucibacillary leprosy cases—a two years follow up at Purulia, India. Casablanca, M. N. and Nayagam, A. S. (A)	339
The effect of leprosy relapse on the basic elimination of leprosy. Yang, X.-Q., <i>et al.</i> . . . (A)	334
Tubercloid relapse in lepromatous leprosy. Waters, M. F. R. and Ridley, D. S. (A)	307
When do relapses appear after treatment of MB leprosy with rifampicin containing regimens? Pattyn, S. R., <i>et al.</i> (A)	336

Rifampin,

[Adverse effect of intermittent use of rifampin for leprosy treatment.] Papaiordanou, P. M. de O., <i>et al.</i> (A)	708
Attempts to select rifampicin-resistant <i>M. leprae</i> in nude mice. McDermott-Lancaster, R. D., <i>et al.</i> (A)	350
Comparative <i>in vitro</i> and <i>in vivo</i> activity of rifabutin and rifampicin against <i>M. avium</i> complex. Saito, H., <i>et al.</i> (A)	150
Evaluation of three short term regimens containing rifampin for treatment of paucibacillary leprosy. Katoch, K., <i>et al.</i> (A)	340
Flu like syndrome with rifampicin pulse therapy. Parking, A. A. and Shah, B. H. (A)	894
Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of 25 mg per kg rifampin. Cartel, J.-L., <i>et al.</i> (O)	810
[Intermittent treatment with rifampin compared to intensive treatment in leprosy.] Salafia, A. and Ignatia. (A)	131
Long term follow up of PB patients treated with either a single dose of rifampicin (RMP) followed by one year of DDS (regimen A) or 10 weekly doses of RMP (regimen B). Janssens, L., <i>et al.</i> (A)	340

- M. leprae* persists in patients treated with rifampicin and acedapsona. Gonzalez, A. B., *et al.* (A) 335
- Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampin. Katoch, K., *et al.* (O) 458
- Rifampicin induced uterine bleeding. Nigam, P. K., *et al.* (A) 130
- Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Grosset, J. H., *et al.* (O) 607
- The effect of treatment with rifampicin, clofazimine and dapsone in multibacillary leprosy in the field for three years. Li, W.-Z., *et al.* (A) 341
- Traitement de la lèpre rurale par une dose unique de rifampicine complétée par l'association sulfone clofazimine en autotraitement. Languillon, J. L. (A) 341
- When do relapses appear after treatment of MB leprosy with rifampicin containing regimens? Pattyn, S. R., *et al.* (A) 336
- Sarcoidosis,**
[HLA-DR phenotype and B/DR haplotype in patients with sarcoidosis.] Ketova, N. A. (A) 729
- Senegal,**
[Epidemiologic study of the orodental health of the lepers in MBalling (MBour-Senegal).] Ndiaye, N., *et al.* (A) 572
- Une "cordonnerié mobile" pour les malades hanséniens du Senegal: 4 ans d'évolution. Parent, M., *et al.* (A) 343
- Sensation(s),**
An evaluation of the Semmes-Weinstein 6.10 monofilament as compared with 6 nylon in leprosy patients. Dorairaj, A., *et al.* (A) 147
- Protective sensation in the foot in leprosy. Hammond, C. J. and Klenerman, P. (A) 570
- Sensory evaluation in leprosy patients using nylon filaments. Brandsma, J. W., *et al.* .. (A) 306
- Sensitivity, drug,**
Measurement of ATP content of *M. leprae*—its application to the determination of viability and drug sensitivity screening. Katoch, V. M., *et al.* (A) 321
- Serodiagnosis,**
A trial to compare serodiagnostic tests for leprosy. Abe, M., *et al.* (A) 303
- Evaluation of a phenolglycolipid antigen (PGL-Tb 1) from *M. tuberculosis* in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., *et al.* (A) 917
- Evaluation of natural phenolic glycolipid (GPI) and artificial antigen in the serodiagnosis of leprosy. Wu, Q.-Z., *et al.* (A) 305
- Gelatin particle agglutination test for serodiagnosis of leprosy—a new simple test useful for field application. Izumi, S., *et al.* (A) 304
- Serodiagnosis of leprosy infection in 9 banded armadillos. Eggelte, T. A., *et al.* (A) 310
- Serum,**
Antineural antibodies in leprosy sera: further characterization of the antigens. Benjamins, J. A., *et al.* (A) 711
- [Assay of antibody level in sera of leprosy patients with *M. smegmatis* ELISA.] Wu, Q., *et al.* (A) 718
- Comparative studies of serum IgA1, IgA2 and IgM against phenolic glycolipid I in leprosy patients and contacts. Chujor, C. S. N., *et al.* (A) 304
- Conformational changes in the IgG molecule of lepromatous sera using laser Raman spectroscopy. Kumar, P., *et al.* (A) 138
- Detection of phenolic glycolipid I of *M. leprae* and antibodies to the antigen in sera from leprosy patients and their contacts. Cho, S.-N., *et al.* (A) 897
- Failure to detect antibodies to HIV-1 in sera from patients with mycobacterial infections. Malkovsky, M., *et al.* (C) 866
- Influence of *in vitro* administered immune complexes on serum levels of complement and circulating immune complexes in *M. leprae* infected mice. Vaishnavi, C., *et al.* (A) 586
- Interaction of anti-leprosy drugs with the rat serum complement system. Sahu, A., *et al.* (A) 131
- Interleukin-2 receptors in the sera of leprosy patients. Ganguly, N. K., *et al.* (C) 870

Monoclonal antibody based double antibody sandwich assay for detection of antigen in serum of leprosy patients. Patil, S. A., <i>et al.</i> (A)	303
Recognition of mycobacterial antigens by sera from patients with leprosy. Vega-Lopez, F., <i>et al.</i> (A)	581
Serum antibodies of normals and leprosy patients show equal binding to a peripheral nerve. Ghaswala, P. S., <i>et al.</i> (C)	690
Serum antibodies to defined carbohydrate antigens during the course of treated leprosy. Gelber, R. H., <i>et al.</i> (O)	744
Serum antibody responses to mycobacteria in leprosy patients and their contacts. Cree, I. A., <i>et al.</i> (A)	576
Serum ferritin in lepra reactions. Saha, K., <i>et al.</i> (C)	867
Serum immune complexes in erythema nodosum leprosum reactions of leprosy. Dharma Rao, T. and Rao, P. R. (A)	133
Serum lactate dehydrogenase in murine leprosy: source and isozymes. Luna Herrera, J. and Rojas-Espinosa, O. (O)	641
Solubilization of preformed immune complexes in sera of lepromatous patients with erythema nodosum leprosum. Chakrabarty, A. K., <i>et al.</i> (A)	311
Skin,	
Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. Karanth, S. S., <i>et al.</i> (A)	578
Histopathologic observations on the persistence of <i>M. leprae</i> in the skin of multibacillary leprosy patients under chemotherapy. Wabitsch, K. R. and Meyers, W. M. (A)	581
Non-cultivable mycobacteria in ulcers of the skin. Salem, J. I., <i>et al.</i> (A)	920
Skin lesion in strain 13 guinea pigs induced by a human non-myelin antigen in dorsal roots. Crawford, C. L., <i>et al.</i> (A)	308
Survival of <i>Staphylococcus epidermidis</i> on the skin of patients with lepromatous leprosy. Kumar, B., <i>et al.</i> (A)	134
The control of infective skin diseases—the lessons of leprosy research. Hay, R. J. (A)	564
The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., <i>et al.</i> (A)	577
Tuberculoïd granuloma in a clinically normal looking skin. Haldar, S. R., <i>et al.</i> (A)	133
Skin smear(s),	
Reliability of direct skin smear microscopy in leprosy. Gupte, M. D., <i>et al.</i> (A)	570
The bacteriological examination of slit-skin smears in leprosy control programmes using multiple drug therapy: a plea for radical changes in current operational methodology. Georgiev, G. D. and McDougall, A. C. (A)	570
Skin test(s),	
A critique on the interpretation of the lepromin reaction using heat-killed <i>M. leprae</i> vaccine. Mistry, N. F. and Antia, N. H. (C)	110
BCG infection induces responsiveness to dead <i>M. leprae</i> in hamsters; a Mitsuda-like reaction. Mariano, M. and Ferreira, C. S. A. (A)	902
Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., <i>et al.</i> (A)	914
[Correlation between skin tests and the production of gamma-interferon in patients with hanseniasis.] Suso, L., <i>et al.</i> (A)	905
Do environmental mycobacteria influence the distribution of disease in the leprosy spectrum? Bacteriological and skin test studies carried out in Iran. Velayati, A., <i>et al.</i> (A)	320
Identification of “high risk group” of leprosy in children using serological and lepromin test: a preliminary report. Naik, S. S., <i>et al.</i> (A)	910
Lepromin conversion induced by a “subunit” vaccine from ICRC bacilli. Bhatki, W. S., <i>et al.</i> (A)	136
Lymphocyte blastogenesis and lepromin reactivity in leprosy patients and their parents. Foss, N. T., <i>et al.</i> (A)	311
PGL-I independence of the lepromin (Mitsuda) reaction in pre-sensitized guinea pigs. Krotoski, W. A., <i>et al.</i> (A)	309
Relative cross reactivity of habanin, lepromin and tuberculin in guinea pigs sensitized with homologous and heterologous mycobacteria. Singh, N. B., <i>et al.</i> (A)	140

- Reply by Gill, Mustafa and Godal (a critique on the interpretation of the lepromin reaction using heat-killed *M. leprae* vaccine). Gill, H. K., *et al.* (C) 112
- Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Ly, H. M., *et al.* (A) 724
- Skin test studies on close contacts of leprosy patients in India. Lord, R., *et al.* (O) 801
- Specific anti-*M. leprae* PGL-I antibodies and Mitsuda reactions in the management of household contacts in New Caledonia. Desforges, S., *et al.* (O) 794
- Ten-year study of lepromin response in child contacts of leprosy patients. Ramu, G. ... (A) 715
- The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* (A) 577
- The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* (A) 579
- Un traitement logique des névrites lépreuses tuberculoides et borderline aiguës ou subaiguës: la désensibilisation progressive à la lépromine. Saint-André, P., *et al.* (A) 339
- Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. (A) 334
- Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., *et al.* (O) 45
- Vaccination and skin test studies on the children of leprosy patients. Stanford, J. L., *et al.* (O) 38
- Spain,**
- Analisis de los registros de lepra en Espana. Garranza Martinez, J. M., *et al.* (A) 323
- [Clinico-diagnostic aspects of leprosy in the province of Jaen (Spain).] Extremera Castillo, F., *et al.* (A) 569
- Fontilles international courses 1989. (N) 558
- Reorientacion del Instituto Leprológico de Trillo para su integracion en el marco de la reforma sanitaria en Espana. Carrasco Gellida, S., *et al.* (A) 351
- Sri Lanka,**
- The current state of leprosy control activities in Sri Lanka. Dewapura, D. R. (A) 910
- Stain(s),**
- [Determination of the viability of *M. leprae* with fluorescent staining.] Meng, M., *et al.* (A) 584
- Effect of chemotherapy on viability of *M. leprae* as determined by ATP content, morphological index and FDA-EB fluorescent staining. Katoch, V. M., *et al.* (O) 615
- Fluorescent staining procedure (FDA/EB) for determining the viability of *M. leprae*. Meng, M.-B., *et al.* (A) 322
- Steroids,**
- Relapse or reversal reaction: the case for a therapeutic trial of steroids. Ramachandran, A. and Seshadri, P. S. (A) 135
- Subclinical,**
- Immuno-epidemiological studies on subclinical infection in leprosy. Bharadwaj, V. P., *et al.* (A) 329
- Immunodiagnostic approaches to the early detection of subclinical infection in leprosy. Bharadwaj, V. P. (A) 574
- Immunoepidemiological studies on subclinical infection among leprosy household contacts in Thailand. Sampattavanich, S., *et al.* (O) 752
- Subclinical infection and the relative risk of developing leprosy: a statistical approach. Rajagopalan, M. S., *et al.* (A) 911
- Sulfones (see also Dapsone),**
- Biorésistance en général—chimiorésistance comparée sulfonorésistance du bacille de Hansen ce qu'il faut firé en verité pour gagner le combat contre la lèpre. Floch, H. A. and Floch, H. H. (A) 566
- [Hanseniasis and pregnancy; an evaluation of sulfone therapy.] dos Santos, I. B., *et al.* (A) 707
- The story of sulfones in tropical medicine and dermatology. Wozel, G. (A) 707
- Traitement de la lèpre rurale par une dose unique de rifampicine complétée par l'association sulfone clofazimine en autotraitement. Languillon, J. L. (A) 341

Surgery,

- A modification of the surgical correction of the thumb—a long term follow up. Beine, A. O., *et al.* (A) 725
- Etude épidémiologique des déformations chirurgicalement curables de 1059 patients hanséniens en zone rurale. Gaisne, E., *et al.* (A) 314
- Motivation and training for reconstructive surgery and rehabilitation in a South American setting. Duerksen, F., *et al.* (A) 347

Switzerland,

- Grants for social and economic research in tropical diseases. (N) 703
- New type TDR grant for scientist. (N) 559
- Report available on joint meeting for leprosy field research. (N) 703
- Report of Fifth Meeting Ad Hoc Drug Development Subgroup of the THELEP SWG. (N) 886
- Report of Fifth Meeting of THELEP SWG. (N) 886
- TDR research capability strengthening. (N) 703
- TDR support for telefax equipment. (N) 559

Taiwan,

- An epidemiological study on leprosy in southern Taiwan. Chou, P., *et al.* (A) 330

Tetanus,

- Tetanus in leprosy patient (II). Anilkumar, G., *et al.* (A) 132
- Tetanus in leprosy patients: report of 5 cases. Hodes, R. M. and Teferedegne, B. (A) 307
- Tetanus in patients with lepromatous leprosy (I). Anilkumar, G., *et al.* (A) 132
- Tetanus with leprosy. Tibrewala, K. D., *et al.* (A) 896

Thailand,

- Immunoepidemiological studies on subclinical infection among leprosy household contacts in Thailand. Sampattavanich, S., *et al.* (O) 752
- Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* (A) 339

Thalidomide,

- Inefficacy of thalidomide on rat adjuvant-induced arthritis and lack of arthrogenicity of Hansen bacilli. Tsutsumi, S. and Gidoh, M. (A) 721
- Thalidomide for treatment of graft-versus-host disease. Vogelsang, G. B., *et al.* (A) 732
- Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Youle, M., *et al.* (A) 733

The Leprosy Mission (TLM),

- Awards to TLM staff. (N) 560
- The Leprosy Mission International change of address. (N) 119

THELEP (WHO Chemotherapy of Leprosy Scientific Working Group),

- Proceedings of the Joint Meeting of Indian and Chemotherapy of Leprosy (THELEP) Scientists on Multidrug Therapy in Leprosy, March 14–15, 1988.* (B) 124
- Progress in chemotherapy research under THELEP programme. Ji, B.-H., *et al.* (A) 336
- Report of Fifth Meeting Ad Hoc Drug Development Subgroup of the THELEP SWG. (N) 886
- Report of Fifth Meeting of THELEP SWG. (N) 886

Therapy (see also Chemotherapy, Multidrug therapy),

- Field trials of combined therapy in lepromatous leprosy. Vijayakumaran, P., *et al.* (A) 337
- Flu like syndrome with rifampicin pulse therapy. Parking, A. A. and Shah, B. H. (A) 894
- [Hanseniasis and pregnancy; an evaluation of sulfone therapy.] dos Santos, I. B., *et al.* (A) 707
- Investigations into the haemolytic effects of dapsone therapy in leprosy patients. Balakrishnan, S., *et al.* (A) 707

Tissue(s),

- Glomerular immunoglobulin deposition in the absence of tissue damage in murine leprosy. Rojas-Espinosa, O., *et al.* (C) 879
- Human monoclonal antibodies to phenolic glycolipid-I from leprosy patients crossreact with poly(ADP-ribose) polynucleotides and tissue bound antigens. Zumla, A., *et al.* (A) 582

- Identification of *M. leprae* antigens in tissues of leprosy patients using monoclonal antibodies. Khanolkar, S. R., *et al.* (O) 652
- Mouse footpad pathogenicity of the chemoautotrophic nocardioform isolates from human and mouse footpad leprosy tissues. Pal, N. K., *et al.* (A) 308
- Viability of *M. leprae* in soil and dead armadillo tissue and its significance. Harris, E. B., *et al.* (A) 323
- Training,**
- Application of a health education model to obtain early and regular treatment of leprosy patients. Matthews, C. M. E. (E) 844
- Courses at a specialist leprosy hospital for the training of medical students and paramedical workers in Nigeria. Attah, E. B. and Davies, E. M. (A) 347
- Involvement of students in a leprosy health education programme—an experiment. Naik, S. S., *et al.* (A) 128
- Karigiri Video teaching/training materials. (N) 701
- Knowledge and attitude of leprosy workers: a case study in status analysis. Wele, D. S. (A) 348
- Leprosy teaching in medical colleges in Bombay—a questionnaire study. Sheela, G. R., *et al.* (A) 890
- Monitoring and evaluation of training programmes. Chacko, P., *et al.* (A) 346
- Motivating and training for reconstructive surgery and rehabilitation in a South American setting. Duerksen, F., *et al.* (A) 347
- Operational efficiency of paramedical workers in leprosy survey: a time motion study. Kumar, A., *et al.* (A) 330
- Orientation in Leprosy for Doctors.* (N) 119
- Training needs for leprosy eradication through primary health care. Thangaraj, E. S. (A) 348
- The application of a health education model to obtain early and regular treatment of leprosy patients. Matthews, C. M. E. (A) 347
- Trials,**
- Field trials of combined therapy in lepromatous leprosy. Vijayakumaran, P., *et al.* (A) 337
- Interpretation of published papers on controlled clinical trials. Waters, M. F. R. (C) 556
- Joint chemotherapy trials in lepromatous leprosy conducted in Korea, The Philippines and Thailand (final report). Cellona, R., *et al.* (A) 339
- Results of one year of phase II/phase III trials with the candidate antileprosy vaccine *Mycobacterium w.* Zaheer, S. A., *et al.* (A) 351
- Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M. (A) 334
- Tuberculin,**
- Concentration dependent functional responsiveness to subcellular antigenic extracts of BCG and different mycobacterial PPDs, of tuberculin (Mtb-PPD) reactive human T-cell lines. Das, P. K., *et al.* (A) 914
- Lymphocytic purine metabolic disorders in tuberculin anergic mice. Senesi, S., *et al.* (A) 594
- Relative cross reactivity of habanin, lepromin and tuberculin in guinea pigs sensitized with homologous and heterologous mycobacteria. Singh, N. B., *et al.* (A) 140
- Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Ly, H. M., *et al.* (A) 724
- The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. Kaplan, G., *et al.* (A) 577
- The relationship between reactivities to lepromin A and soluble protein antigen of *M. leprae* and tuberculin. Pemajayantha, V., *et al.* (A) 579
- Tuberculoid leprosy,**
- Calcification of ulnar nerve in a patient with tuberculoid leprosy—a case report. Siddappa, K., *et al.* (A) 711
- Destruction of ala nasi and loss of columella in borderline tuberculoid leprosy—a case report. Siddappa, K., *et al.* (A) 711
- Serological responses of patients with lepromatous and tuberculoid leprosy to 30-, 31-, and 32-kilodalton antigens of *M. tuberculosis*. Rumschlag, H. S., (A) 140
- Tuberculoid leprosy on hairy scalp: a case report. Ghorpade, A., *et al.* (A) 133
- [Tuberculoid leprosy with necrotizing neuritis and numerous bacilli in the fistulae.] de Menezes, J. A., *et al.* (A) 569

Tuberculosis,

A competition ELISA for the detection of mycobacterial antigen in tuberculosis exudates. Ramkisson, A., <i>et al.</i> (A)	730
[A nutritional survey in leprosy and tuberculosis patients.] Zhou, D., <i>et al.</i> (A)	726
Amoebic disease precipitated by corticosteroids prescribed for tuberculous pleural effusions. Ratcliffe, G. E. (A)	731
An analysis of pulmonary tuberculosis data in Taiwan and Korea. Schulzer, M., <i>et al.</i> (A)	151
Association of tuberculosis and <i>M. tuberculosis</i> -specific antibody levels with HLA. Bothamley, G. H., <i>et al.</i> (A)	727
[Changes in the system of T-lymphocyte cyclic nucleotides in animals with experimental tuberculosis.] Kostromin, A. P., <i>et al.</i> (A)	591
[Classes I and II antigens and levels of IgG antibodies in patients with infiltrative tuberculosis of the lungs.] Nikolayan, L. T., <i>et al.</i> (A)	918
[Determination of antibodies to mycobacterial antigens in tuberculosis by the method of erythroimmunoabsorption with a rosette marker.] Plaksin, D. Y., <i>et al.</i> (A)	140
Epidemic of pulmonary tuberculosis in geriatric homes. Morris, C. D. W. and Nell, H. (A)	149
Evaluation of a phenoglycolipid antigen (PGL-Tb 1) from <i>M. tuberculosis</i> in the serodiagnosis of tuberculosis: comparison with PPD antigen. Martin-Casabona, N., <i>et al.</i> (A)	917
Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council (A)	591
Identification of mycobacterial antigens for "ELISA" serology in the diagnosis of leprosy and tuberculosis. Das, P. K., <i>et al.</i> (A)	898
Immunological response to homologous and heterologous phenolic glycolipid antigens in tuberculosis and leprosy. Torgal-Garcia, J., <i>et al.</i> (A)	905
<i>In vitro</i> activity of ciprofloxacin in combination with standard antituberculous drugs against <i>M. tuberculosis</i> . Uttley, A. H. C. and Collins, C. H. (A)	151
<i>In vitro</i> analysis of the cellular mechanisms involved in immunity to tuberculosis. Kaufmann, S. H. E. (A)	729
Longhouse dwelling, social contact and the prevalence of leprosy and tuberculosis among native tribes of Sarawak. Chen, P. C. Y. (A)	145
New experimental drugs for the treatment of tuberculosis. Parenti, F. (A)	730
Preliminary evaluation of a <i>M. tuberculosis</i> phenoglycolipid antigen in the serologic diagnosis of tuberculosis. Torgal-Garcia, J., <i>et al.</i> (A)	151
Prevalence of HIV infection among patients with leprosy and tuberculosis in rural Zambia. Meeran, K. (A)	709
Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Brown, A. R., <i>et al.</i> (A)	913
Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Mehta, P. K. and Khuller, G. K. (A)	592
[Tuberculosis and anti-HIV seropositivity in Kinshasa, Zaire.] Williams, J. C., <i>et al.</i> (A)	921
<i>Tuberculosis and Leprosy</i> by Richard J. W. Rees. Cowley, S. A. (B)	888
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., <i>et al.</i> (O)	45

Turkey,

Close-contact surveys and mass-screening studies for leprosy in Turkey. Aytekin, A. H. and Saylan, T. (A)	143
Leprosy in Turkey. Aytekin, A. H. and Saylan, T. (A)	144
The characteristics and mode of detection of the new patients encountered in the leprosy endemic province of Van within the last five years. Saylan, T., <i>et al.</i> (A)	324
The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey; a preliminary study. Cem Mat, M., <i>et al.</i> (A)	144

U.K.,

Application for LEPRAs research grants in U.K. (N)	559
Awards to TLM staff. (N)	560
Leprosy—a learning package—The Wellcome Tropical Institute. (N)	887

- Robert Cochrane Fund for Leprosy.(N) 703
 The Leprosy Mission International change of address.(N) 119
 Wellesley Bailey Scholarship.(N) 560
- Ulcer(s),**
 Bacterial flora of ulcers treated by three types of dressings. Cherian, E., *et al.*(A) 132
 Carcinoma in plantar ulcers of leprosy patients. Majoroh, T. O. and Imongan, W. I.(A) 709
 Malignant transformation of trophic ulcer in leprosy. Anilkumar, G., *et al.*(A) 132
 Non-cultivable mycobacteria in ulcers of the skin. Salem, J. I., *et al.*(A) 920
 Occlusive hydrocolloid dressings applied to chronic neuropathic ulcers. A study of efficacy in patients in a rural south Indian hospital. Mumford, J. W. and Mumford, S. P.(A) 148
 Relationship between hallux limitus and ulceration of the great toe. Birke, J. A., *et al.*(A) 725
 Squamous cell carcinoma in trophic ulcer in leprosy. Naik, R., *et al.*(A) 134
 Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Youle, M., *et al.*(A) 733
- Ultrastructure (see also Electron Microscopy),**
 New data on the ultrastructure of the membrane of *M. leprae*. Silva, M. T., *et al.*(O) 54
- Urine,**
 Detection of a specific *M. leprae* antigen in the urine of leprosy patients. Mahon, A. C., *et al.*(A) 326
- U.S.A.,**
 Comparison of the distribution of indigenous human and armadillo leprosy in Louisiana, U.S.A. Truman, R. W. and Kumaresan, J. A.(A) 334
 Damien-Dutton 1988 award to Hermann Kober.(S) 252
 Leprosy cases, 1978–1987.(N) 119
 Leprosy in six isolated residents of northern Louisiana. West, B. C., *et al.*(A) 147
 Number of new leprosy patients.(N) 561
 Regional Hansen's disease centers.(N) 119
 2nd Annual Course on Infectious, Parasitic and Tropical Diseases.(N) 704
 The Heiser Program for Research in Leprosy 1990.(N) 887
 12th International Conference on Missionary Medicine.(N) 704
- Vaccination,**
 Comments on leprosy vaccination. Kato, L.(C) 693
 Cure of bacille Calmette-Guérin vaccination abscesses with erythromycin. Murphy, P. M., *et al.*(A) 729
 Hypothesis: Does vaccination with bacille Calmette-Guérin protect against AIDS? Kalenius, G., *et al.*(A) 729
 Implications of prior BCG vaccination programmes in the community on the protective efficacy of new antileprosy vaccines. Radhakrishna, S., *et al.*(A) 588
 Prospects for new generation vaccines for leprosy: progress, barriers and future strategies. Watson, J. D.(E) 834
 [The leprosy bacillus; expectations for culturing and vaccination.] Portaels, F.(A) 585
 Use of skin tests with *M. leprae* soluble antigen for epidemiological studies and vaccination trials. Zuniga, M.(A) 334
 Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis. Ghazi Saidi, K., *et al.*(O) 45
 Vaccination and skin test studies on the children of leprosy patients. Stanford, J. L., *et al.*(O) 38
 Vaccination of mice against *M. leprae* infection. Singh, N. B., *et al.*(A) 717
- Veins,**
Nerves and Veins in Leprosy by A. Mukherjee. Dharmendra.(B) 888
 Vascular involvement in leprosy. Kaur, S. and Abraham, A.(A) 901
- Venezuela,**
Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday by the World Health Organization.(B) 122

World Health Organization (WHO),

- A Guide to Leprosy Control* (2nd ed.) by the World Health Organization. (B) 124
- Multidrug Therapy for Leprosy: An End in Sight. How Five Countries, India, Ethiopia, Malawi, Venezuela, Brazil, are Using Drugs of Today to Make Leprosy a Disease of Yesterday* by the World Health Organization. (B) 122
- Sixth Report of the WHO Expert Committee on Leprosy. (B) 125

Zaire,

- [Tuberculosis and anti-HIV seropositivity in Kinshasa, Zaire.] Williams, J. C., *et al.* . . (A) 921

Zambia,

- Prevalence of HIV infection among patients with leprosy and tuberculosis in rural Zambia. Meeran, K. (A) 709

Zimbabwe,

- Multiple drug therapy in Zimbabwe. Matemera, B. O. (A) 336

Zinc,

- Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. de Bruyn, J., *et al.* (A) 590
- Study of serum zinc level in leprosy. Saxena, N., *et al.* (A) 573